ZyVersa Therapeutics (ZVSA) S-1 14 Jun 23 IPO registration Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2023
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Contact Personnel Name	Stephen C. Glover

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Successor	Predecessor
Current Assets:
Cash	$ 5,902,199	$ 5,902,199	$ 1,278,073	$ 5,902,199
Prepaid expenses and other current assets	225,347	225,347	1,321,551	225,347
Vendor deposits	235,000	235,000	235,000	235,000
Total Current Assets	6,362,546	6,362,546	2,834,624	6,362,546
Equipment, net	17,333	17,333	14,733	17,333
In-process research and development	100,086,329	100,086,329	100,086,329	100,086,329
Goodwill	11,895,033	11,895,033	11,895,033	11,895,033
Security deposit	46,659	46,659	46,659	46,659
Operating lease right-of-use asset	98,371	98,371	76,324	98,371
Vendor deposit
Total Assets	118,506,271	118,506,271	114,953,702	118,506,271
Current Liabilities:
Accounts payable	6,025,645	6,025,645	6,381,086	6,025,645
Accrued expenses and other current liabilities	2,053,559	2,053,559	2,112,812	2,053,559
Operating lease liability	108,756	108,756	84,507	108,756
Derivative liabilities					$ 560,600
Convertible notes payable (net of $0 and $39,942 debt discount as of December 31, 2022 and 2021, respectively)
Convertible notes payable related parties
Total Current Liabilities	8,187,960	8,187,960	8,578,405	8,187,960
Deferred tax liability	10,323,983	10,323,983	9,276,932	10,323,983
Total Liabilities	18,511,943	18,511,943	17,855,337	18,511,943
Commitments and contingencies (Note 10)
Redeemable Common Stock, subject to possible redemption	331,331	331,331		331,331
Stockholders’ Equity (Deficiency):
Common stock, value	902	902	922	902
Additional paid-in-capital	104,583,271	104,583,271	105,562,569	104,583,271
Accumulated deficit	(4,921,178)	(4,921,178)	(8,465,128)	(4,921,178)
Total Stockholders’ Equity (Deficiency)	99,662,997	99,662,997	97,098,365	99,662,997
Total Liabilities, Temporary Equity and Stockholders’ Equity (Deficiency)	118,506,271	118,506,271	114,953,702	118,506,271
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]					Predecessor
Current Assets:
Cash					$ 328,581
Prepaid expenses and other current assets					106,929
Vendor deposits					376,272
Total Current Assets					811,782
Equipment, net					27,733
In-process research and development
Goodwill
Security deposit					46,659
Operating lease right-of-use asset
Vendor deposit					240,000
Total Assets					1,126,174
Current Liabilities:
Accounts payable					2,000,100
Accrued expenses and other current liabilities					1,914,101
Operating lease liability
Derivative liabilities					560,600
Convertible notes payable (net of $0 and $39,942 debt discount as of December 31, 2022 and 2021, respectively)					5,976,508
Convertible notes payable related parties					3,175,000
Total Current Liabilities					13,626,309
Deferred tax liability
Total Liabilities					13,626,309
Commitments and contingencies (Note 10)
Redeemable Common Stock, subject to possible redemption					331,331
Stockholders’ Equity (Deficiency):
Common stock, value					242
Additional paid-in-capital					40,065,109
Accumulated deficit					(52,896,817)
Total Stockholders’ Equity (Deficiency)					(12,831,466)
Total Liabilities, Temporary Equity and Stockholders’ Equity (Deficiency)					1,126,174
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficiency):
Preferred stock, value	1	1	1	1
Series A Preferred Stock [Member] | Predecessor [Member]
Stockholders’ Equity (Deficiency):
Preferred stock, value
Series B Preferred Stock [Member]
Stockholders’ Equity (Deficiency):
Preferred stock, value	$ 1	$ 1	$ 1	$ 1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)		1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt discount	$ 0	$ 0		$ 0	$ 39,942
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Successor	Predecessor
Temporary equity, shares outstanding	65,783	65,783	0	65,783
Preferred stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	110,000,000	110,000,000	110,000,000	110,000,000
Common stock, shares issued	9,016,139	9,016,139	9,211,922	9,016,139
Common stock, shares outstanding	9,016,139	9,016,139	9,211,922	9,016,139
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]					Predecessor
Temporary equity, shares outstanding					331,331
Common stock, par value					$ 0.00001
Common stock, shares authorized					75,000,000
Common stock, shares issued					24,167,257
Common stock, shares outstanding					24,167,257
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635	8,635	8,635
Preferred stock, shares issued	8,635	8,635	8,635	8,635
Preferred stock, shares outstanding	8,635	8,635	8,635	8,635
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062	5,062	5,062	5,062
Preferred stock, shares issued	5,062	5,062	5,062	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062	5,062	5,062	5,062

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Predecessor	Predecessor	Predecessor
Operating Expenses:
Research and development	$ 399,894	$ 1,055,943
General and administrative	420,174	3,536,136
Total Operating Expenses	820,068	4,592,079
Loss From Operations	(820,068)	(4,592,079)
Other (Income) Expense:
Interest (income) expense		(1,078)
Interest expense
Change in fair value of derivative liabilities				$ (607,001)	$ (228,100)
Gain on forgiveness of PPP Loan
Pre-Tax Net Loss	(820,068)	(4,591,001)
Income tax benefit	745,050	1,047,051
Net Loss	(75,018)	$ (3,543,950)
Deemed dividend to preferred stockholders
Net Loss Attributable to Common Stockholders	$ (75,018)
Net Loss Per Share
- Basic and Diluted	$ (0.01)	$ (0.39)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	9,016,139	9,128,488
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]			Predecessor	Predecessor	Predecessor
Operating Expenses:
Research and development			$ 1,066,962	$ 5,407,859	$ 2,124,277
General and administrative			2,301,369	7,605,205	5,580,099
Total Operating Expenses			3,368,331	13,013,064	7,704,376
Loss From Operations			(3,368,331)	(13,013,064)	(7,704,376)
Other (Income) Expense:
Interest (income) expense			168,064
Interest expense				427,542	821,366
Change in fair value of derivative liabilities			212,100	607,001	(228,100)
Gain on forgiveness of PPP Loan					(213,481)
Pre-Tax Net Loss			(3,748,495)	(14,047,607)	(8,084,161)
Income tax benefit
Net Loss			$ (3,748,495)	(14,047,607)	(8,084,161)
Deemed dividend to preferred stockholders				(10,015,837)
Net Loss Attributable to Common Stockholders				$ (24,063,444)	$ (8,084,161)
Net Loss Per Share
- Basic and Diluted			$ (0.16)	$ (0.99)	$ (0.33)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted			24,167,257	24,194,270	24,167,257

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)		Total	Predecessor [Member]	Preferred Stock [Member]	Preferred Stock [Member] Predecessor [Member]		Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Predecessor [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member] Predecessor [Member]	Common Stock [Member]	Common Stock [Member] Predecessor [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Predecessor [Member]	Retained Earnings [Member]	Retained Earnings [Member] Predecessor [Member]
Balance at Dec. 31, 2020			$ (8,889,041)									$ 242		$ 35,923,373		$ (44,812,656)
Balance, shares at Dec. 31, 2020												24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor	Predecessor
Stock-based compensation			$ 4,141,736											4,141,736
Net loss			(8,084,161)													(8,084,161)
Balance at Dec. 31, 2021			$ (12,831,466)									$ 242		40,065,109		(52,896,817)
Balance, shares at Dec. 31, 2021												24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor	Predecessor
Stock-based compensation			$ 1,941,746											1,941,746
Net loss			(3,748,495)													(3,748,495)
Issuance of preferred stock in private placement	[1]		393,301					$ 1						393,300
Issuance of preferred stock in private placement, shares	[1]							133,541
Balance at Mar. 31, 2022			(14,244,914)					$ 1				$ 242		42,400,155		(56,645,312)
Balance, shares at Mar. 31, 2022								133,541				24,167,257
Balance at Dec. 31, 2021			$ (12,831,466)									$ 242		40,065,109		(52,896,817)
Balance, shares at Dec. 31, 2021												24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor	Predecessor
Stock-based compensation			$ 3,524,801											3,524,801
Net loss			(14,047,607)													(14,047,607)
Issuance of preferred stock in private placement	[2]		1,865,384		$ 6									1,865,378
Issuance of preferred stock in private placement, shares	[2]				625,639
Conversion of convertible notes payable into preferred stock	[3]		5,658,888		$ 18									5,658,870
Conversion of convertible notes payable into preferred stock, shares		2,940,537			1,802,193	[3]
Conversion of preferred stock into common stock					$ (24)							$ 64		(40)
Conversion of preferred stock into common stock, shares					(2,427,832)							6,406,210
Conversion of convertible notes payable into common stock	[4]		5,838,209									$ 29		5,838,180
Conversion of convertible notes payable into common stock, shares	[4]											2,940,537
Balance at Dec. 12, 2022		$ 99,681,682	(9,991,791)	$ 0	$ 0		$ 1	1	$ 1	1	$ 902	$ 335	$ 104,526,938	56,952,298	$ (4,846,160)	(66,944,424)
Balance, shares at Dec. 12, 2022							8,635		5,062		9,016,139	33,514,004
Balance at Dec. 31, 2021			(12,831,466)									$ 242		40,065,109		(52,896,817)
Balance, shares at Dec. 31, 2021												24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Successor
Balance at Dec. 31, 2022		$ 99,662,997					$ 1		$ 1		$ 902		104,583,271		(4,921,178)
Balance, shares at Dec. 31, 2022							8,635		5,062		9,016,139
Balance at Dec. 12, 2022		$ 99,681,682	$ (9,991,791)	0	$ 0		$ 1	$ 1	$ 1	$ 1	$ 902	$ 335	104,526,938	$ 56,952,298	(4,846,160)	$ (66,944,424)
Balance, shares at Dec. 12, 2022							8,635		5,062		9,016,139	33,514,004
Financial Designation, Predecessor and Successor [Fixed List]		Successor
Stock-based compensation		$ 56,333											56,333
Net loss		(75,018)													(75,018)
Balance at Dec. 31, 2022		$ 99,662,997					$ 1		$ 1		$ 902		104,583,271		(4,921,178)
Balance, shares at Dec. 31, 2022							8,635		5,062		9,016,139
Financial Designation, Predecessor and Successor [Fixed List]		Successor
Reclassification of formerly redeemable common stock		$ 331,331									$ 7		331,324
Reclassification of formerly redeemable common stock, shares											65,783
Issuance of common stock pursuant to vendor agreements		395,200									$ 13		395,187
Issuance of common stock pursuant to vendor agreements, shares											130,000
Registration costs associated with preferred stock issuance		(34,674)											(34,674)
Stock-based compensation		287,461											287,461
Net loss		(3,543,950)													(3,543,950)
Balance at Mar. 31, 2023		$ 97,098,365					$ 1		$ 1		$ 922		$ 105,562,569		$ (8,465,128)
Balance, shares at Mar. 31, 2023							8,635		5,062		9,211,922
[1]Includes gross proceeds of $ 419,320 26,019 1,964,524 99,140 5,230,000 428,888 3,961,000 709,608 1,167,601

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) (Parenthetical) - USD ($)	3 Months Ended	11 Months Ended
	Mar. 31, 2022	Dec. 12, 2022
Reorganization, Chapter 11 [Line Items]
Debt principal amount		$ 3,961,000
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Gross proceeds	$ 419,320	1,964,524
Issuance costs	$ 26,019	99,140
Predecessor [Member] | Convertible Notes Payable [Member]
Reorganization, Chapter 11 [Line Items]
Debt principal amount		5,230,000
Accrued interest		428,888
Predecessor [Member] | Convertible Notes One Payable [Member]
Reorganization, Chapter 11 [Line Items]
Debt principal amount		3,961,000
Accrued interest		709,608
Derivative liability		$ 1,167,601

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Cash Flows From Operating Activities:
Net loss		$ (75,018)	$ (3,543,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation Options		56,333	287,461
Amortization of debt discount
Gain on forgiveness of PPP Loan
Change in fair value of derivative liability					$ (607,001)		$ (228,100)
Depreciation of fixed assets		532	2,600		9,869
Non-cash rent expense		4,443	22,047
Deferred tax liability		(745,050)	(1,047,051)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		36,606	(701,004)
Security deposit
Vendor deposits		125,645
Accounts payable		(2,076,863)	355,441
Operating lease liability		(4,786)	(24,249)
Accrued expenses and other current liabilities		(715,730)	59,253
Net Cash Used In Operating Activities		(3,393,888)	(4,589,452)
Cash Flows From Financing Activities:
Proceeds from issuance of preferred stock in private placement
Issuance costs associated with preferred stock issuance			(34,674)
Proceeds from issuance of convertible notes payable
Net Cash Provided By Financing Activities			(34,674)
Net (Decrease) Increase in Cash and Restricted Cash		(3,393,888)	(4,624,126)
Cash - Beginning of Period		9,296,087	5,902,199
Cash - End of Period	$ 5,902,199	5,902,199	1,278,073		$ 9,296,087	$ 5,902,199
Non-cash investing and financing activities:
Reclassification of formerly redeemable common stock			331,331
Issuance of common stock pursuant to vendor agreements			395,200
Gain on forgiveness of PPP Loan
Conversion of convertible notes payable and accrued interest into preferred stock
Conversion of convertible notes payable and accrued interest into common stock
Recognition of ROU asset and lease liability upon adoption of ASC 842
Accounts payable for deferred offering costs		240,691
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Cash Flows From Operating Activities:
Net loss				$ (3,748,495)	$ (14,047,607)		$ (8,084,161)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation Options				1,941,746	3,524,801		4,141,736
Amortization of debt discount				32,184	39,492		317,833
Gain on forgiveness of PPP Loan							(213,481)
Change in fair value of derivative liability				212,100	607,001		(228,100)
Depreciation of fixed assets				2,600	9,868		10,400
Non-cash rent expense				20,580	79,918
Deferred tax liability
Changes in operating assets and liabilities:
Prepaid expenses and other current assets				(420,363)	73,675		(318,761)
Security deposit							11,665
Vendor deposits				60,000	255,627		10,000
Accounts payable				1,234,577	6,617,064		(311,862)
Operating lease liability				(22,027)	(86,100)
Accrued expenses and other current liabilities				313,148	1,431,620		(411,358)
Net Cash Used In Operating Activities				(373,950)	(1,494,641)		(5,076,089)
Cash Flows From Financing Activities:
Proceeds from issuance of preferred stock in private placement				419,319	1,964,524
Issuance costs associated with preferred stock issuance				(26,019)	(99,140)
Proceeds from issuance of convertible notes payable							5,230,000
Net Cash Provided By Financing Activities				393,300	1,865,384		5,230,000
Net (Decrease) Increase in Cash and Restricted Cash				19,350	370,743		153,911
Cash - Beginning of Period		$ 699,324		328,581	328,581	$ 328,581	174,670
Cash - End of Period				347,931	699,324		328,581
Non-cash investing and financing activities:
Reclassification of formerly redeemable common stock
Issuance of common stock pursuant to vendor agreements
Gain on forgiveness of PPP Loan							231,481
Conversion of convertible notes payable and accrued interest into preferred stock					5,658,888
Conversion of convertible notes payable and accrued interest into common stock					5,838,209
Recognition of ROU asset and lease liability upon adoption of ASC 842				$ 182,732	182,732
Accounts payable for deferred offering costs					$ 667,224		$ 25,000

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation Organization and Operations Larkspur Health Acquisition Corp. (“Larkspur”), a blank-check special purpose acquisition company, was incorporated in Delaware on March 17, 2021. On December 12, 2022, Larkspur consummated the Business Combination (as defined below) with ZyVersa Therapeutics, Inc. (“Predecessor”) which was incorporated in the State of Florida on March 11, 2014 as Variant Pharmaceuticals, Inc. Pursuant to the terms of the Business Combination Agreement (the “Business Combination Agreement”) (and upon all other conditions of the Business Combination Agreement being satisfied or waived), on the date of the consummation (the “Closing Date”) of the Business Combination and transactions contemplated thereby (the “Business Combination”), Larkspur (“New Parent”) changed its name to ZyVersa Therapeutics, Inc. and the Predecessor changed its name to ZyVersa Therapeutics Operating, Inc. (the “Operating Company”) after merging with a subsidiary of the New Parent, with the Operating Company being the surviving entity, which resulted in it being incorporated in Delaware and it being a wholly-owned subsidiary of the New Parent (collectively the “Successor”). References to the “Company” or “ZyVersa” refer to the Successor for the three months ended March 31, 2023, and to the Predecessor for the three months ended March 31, 2022. ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2023 and for the three months ended March 31, 2023 and 2022. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The accompanying unaudited condensed consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the accounting rules and regulations of the SEC. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements	Note 1 – Business Organization, Nature of Operations and Risks and Uncertainties Business Organization, Nature of Operations and Basis of Presentation Organization and Operations Larkspur Health Acquisition Corp. (“Larkspur”), a blank-check special purpose acquisition company, was incorporated in Delaware on March 17, 2021. On December 12, 2022, Larkspur consummated the Business Combination (see Note 4 – Business Combination for additional details) with ZyVersa Therapeutics, Inc. (“Predecessor”) which was incorporated in the State of Florida on March 11, 2014 as Variant Pharmaceuticals, Inc. On the date of consummation of the Business Combination, Larkspur (“New Parent”) changed its name to ZyVersa Therapeutics, Inc. and the Predecessor changed its name to ZyVersa Therapeutics Operating, Inc. (the “Operating Company”) after merging with a subsidiary of the New Parent, with the Operating Company being the surviving entity, which resulted in it being incorporated in Delaware and it being a wholly-owned subsidiary of the New Parent (collectively the “Successor”). References to the “Company” or “ZyVersa” refer to the Successor for the Successor period from December 13, 2022 to December 31, 2022 and to the Predecessor for the Predecessor period from January 1, 2021 to December 12, 2022. ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Risks and Uncertainties In early 2020, it became evident that there was a global outbreak of SARS-CoV-2, a novel strain of coronavirus that causes Coronavirus disease (COVID-19). At the onset, the Company experienced significant negative impacts on many aspects of its business. These effects included a delay in the launch of the VAR 200 Phase 2a trials as potential patient participants would not be willing to risk going into a facility for the trials. In addition, the private funding markets faltered, which deprived the Company of the necessary liquidity to fund the business. As a result, management implemented significant cost reduction measures to continue until economic conditions improved. The full extent of COVID-19’s future impact on the Company’s operations and financial condition remains uncertain. A prolonged COVID-19 outbreak could have a material adverse impact on the Company’s results of operations, financial condition and liquidity, including the timing and ability of the Company to progress its clinical development initiatives. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On March 10, 2023, Silicon Valley Bank (“SVB”) was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. A statement by the Department of the Treasury, the Federal Reserve and the FDIC stated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts. The standard deposit insurance amount is up to $ 250,000

Going Concern and Management_s

Going Concern and Management’s Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 - Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. As of March 31, 2023, the Company had cash of approximately $ 1.3 5.7 3.5 4.6 8.5 The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, and there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.	Note 2 – Going Concern and Management’s Plans The Company has incurred losses each year since its inception and has a net working capital deficiency as of December 31, 2022. Based upon the cash on hand as of the date the financials were issued, the Company expects that the cash it currently has available will not fund its operations for 12 months from the issuance date of the financial statements. As a result, the Company will be required to raise additional funds through equity or debt financing, and there can be no assurance that it will be successful in securing additional capital. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements. The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. The Company’s cash flow needs include the planned costs to operate its business, including amounts required to fund research and development, working capital, and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. We intend to raise additional capital in the future to fund operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustment that might become necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Since the date the Company’s December 31, 2022 financial statements were issued in its 2022 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 4,101,625 shares if the Successor Series A warrant exercise price resets to its floor price of $ 2.00 per share. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.	Note 3 – Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”). Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. See Note 1 – Risks and Uncertainties. Business Combination In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off. Long-Lived Assets and Goodwill The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other In determining whether a quantitative assessment is required, the Company will evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations. Equipment, Net Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 52,000 34,667 24,267 Successor 532 Predecessor 9,869 Financing Costs Debt issuance costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt financing, are reported as a direct deduction from the face amount of the notes payable and are amortized over the contractual term of the underlying notes payable using the effective interest method. Convertible Promissory Notes The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 “Derivatives and Hedging” (“ASC 815”) of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record any bifurcated embedded features at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded in earnings each period as non-operating, non-cash income or expense. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Bifurcated embedded features are recorded at their initial fair values which create additional debt discount to the host instrument. Prior to the January 1, 2021 adoption of Accounting Standards Update (“ASU”) 2020-06, if the embedded conversion options did not require bifurcation, the Company then evaluated for the existence of a beneficial conversion feature by comparing the fair value of the Company’s underlying stock as of the commitment date to the effective conversion price of the instrument (the intrinsic value). The host instrument is measured at amortized cost with the carrying value being accreted to the stated principal amount of contractual maturity using the effective-interest method with a corresponding charge to interest expense. After the January 1, 2021 adoption of ASU 2020-06, the Company is no longer required to evaluate for the existence of a beneficial conversion feature. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of the Company’s financial instruments, such as cash, accounts payable and investor deposits approximate fair values due to the short-term nature of these instruments. See Note 8 – Derivative Liabilities for additional details regarding the valuation technique and assumptions used in valuing Level 3 inputs. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Leases See Note 3 - Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for further details on the adoption of ASC 842. Research and Development Research and development expenses are charged to operations as incurred. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Fair Value of Stock Options and Warrants The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Successor common stock will be valued using the market approach using the trading prices of the common stock on the Nasdaq Global Market. During 2022, the fair value of the Predecessor common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Predecessor valuation of $ 85 Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor December 31, 2022 December 12, 2022 December 31, 2021 Predecessor warrants [1] - 8,560,561 2,154,351 Successor warrants [1] [5] 8,628,695 - - Predecessor options - 10,039,348 8,755,179 Successor options 1,993,235 - - Predecessor Series A Convertible Preferred Stock - 6,406,210 - Successor Series A Convertible Preferred Stock 863,500 (3) - - Successor Series B Convertible Preferred Stock 506,264 (4) - - Predecessor convertible notes payable [2] - - 3,400,187 Total potentially dilutive shares 11,991,694 25,006,119 14,309,717 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.25 [3] Does not include an additional 3,454,000 [4] Does not include an additional 216,970 [5] Does not include an additional 3,454,000 Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Companies should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to clarify the accounting for certain financial instruments with characteristics of liabilities and equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock by removing the cash conversion model and the beneficial conversion feature model. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in-capital. In addition, this ASU improves disclosure requirements for convertible instruments and earnings-per-share guidance. The ASU also revises the derivative scope exception guidance to reduce form-over-substance-based accounting conclusions driven by remote contingent events. The amendments in this update are effective for our fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption will be permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company early adopted ASU 2020-06 effective January 1, 2021 which eliminated the need to assess whether a beneficial conversion feature needs to be recognized upon the issuance of new convertible instruments. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842).” ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for private companies and emerging growth companies for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on December 31, 2022, effective January 1, 2022 and the adoption of this ASU resulted in the recording of right-of-use assets and lease liabilities for the Company’s operating leases in the approximate amounts of $ 182,732 199,642 16,910 Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 291,552 584,226 Other accrued expenses 51,968 214,229 Federal income tax payable 106,683 106,683 Bonus accrual 764,590 - Registration delay liability [2] 398,019 - Accrued interest Deferred rent Total accrued expenses and other current liabilities $ 2,112,812 $ 2,053,559 [1] See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note. [2] See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.	Note 6 – Accrued Expenses and Other Current Liabilities As of December 31, 2022 and 2021, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities 2022 2021 For the Years Ended December 31, 2022 2021 L&F milestone payment liability $ 1,500,000 $ 1,500,000 L&F Note (351,579 ) (351,579 ) L&F, net 1,148,421 1,148,421 Payroll accrual 584,226 - Other accrued expenses 214,229 - Federal income tax payable 106,683 - Accrued interest - 748,767 Deferred rent - 16,913 Total accrued expenses and other current liabilities $ 2,053,559 $ 1,914,101

Derivative Liabilities

Derivative Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 5 – Derivative Liabilities As of January 1, 2022, the Company had Level 3 derivative liabilities that were measured at fair value at issuance, related to the redemption features and put options of certain convertible notes. The redemption features were valued using a combination of a discounted cash flow and a Black-Scholes valuation technique. There were no During the three months ended March 31, 2022, the Predecessor recorded a gain on the change in the fair value of the derivative liabilities of $ 212,100 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements	Note 8 – Derivative Liabilities As of January 1, 2021, the Company had Level 3 derivative liabilities that were measured at fair value at issuance, related to the redemption features and put options of the Notes. See Note 7 - Convertible Notes Payable for additional details. The redemption features were valued using a combination of a discounted cash flow and a Black-Scholes valuation technique. On December 12, 2022, upon the closing of the Business Combination (see Note 4 – Business Combination), the Notes automatically converted into 2,940,537 1.58835 80 1.98542 5,838,209 186,401 The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Schedule of Changes in Fair Value of Level 3 Derivative Liabilities Beginning balance as of January 1, 2021 $ 788,700 Change in fair value of derivative liabilities (228,100 ) Ending balance as of December 31, 2021 $ 560,600 Change in fair value of derivative liabilities 607,001 Reclassify to equity upon conversion of the Notes (1,167,601 ) Ending balance on December 12, 2022 $ - There were no derivative liabilities as of December 31, 2022. For the derivative liability valuation, as of December 31, 2021, the significant unobservable inputs used in the discounted cash flow were a discount rate of 25 85 0 Schedule of Derivative Liabilities Fair Value Assumption December 31, 2021 Fair value of common stock on date of issuance $ 3.25 Risk free interest rate 0.06 0.19 % Expected term (years) 0.00 0.50 Expected volatility 75 % Expected dividends 0.00 %

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 6 – Income Taxes Income tax expense and the effective tax rate were as follows: Schedule of Income Tax Expense and the Effective Tax Rate Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, (in thousands) 2023 2022 Income tax benefit $ 1,047,051 $ - Effective tax rate 22.81 % 0.00 % The tax provisions for the three months ended March 31, 2023 and 2022 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was 22.81 0.0	Note 9 – Income Taxes The Company is subject to United States federal and state income taxes. The provision for income taxes consists of the following (benefits) provisions: Schedule of Provision For Income Taxes December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor For the period For the period December 13 through January 1 For the year December 31, 2022 December 12, 2022 December 31, 2021 Deferred tax benefit: Federal $ (151,625 ) $ (2,191,344 ) $ (1,480,472 ) State (34,844 ) (482,283 ) (763,612 ) Deferred tax benefit (186,469 ) (2,673,627 ) (2,244,084 ) Change in valuation allowance (558,581 ) 2,673,627 2,244,084 Provision for income taxes $ (745,050 ) $ - $ - The provision for income taxes differs from the Federal statutory rate as follows: Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor For the period For the period December 13 through January 1 through For the year ended December 31, 2022 December 12, 2022 December 31, 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % State tax rate, net of federal benefit 3.6 % 3.6 % 3.7 % Permanent items (1.9 %) (5.4 %) (0.9 %) Nondeductible basis difference 0.0 % 0.0 % 0.1 % Effect of change in state rate 0.0 % (0.1 %) 3.9 % Prior period adjustments and other 0.0 % (0.1 %) 0.0 % Change in valuation allowance 68.1 % (19.0 %) (27.8 %) Effective income tax rate 90.8 % (0.0 %) 0.0 % Deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 12, 2022 December 31, 2021 Successor Predecessor Predecessor Successor Predecessor December 31, 2022 December 12, 2022 December 31, 2021 Net operating loss carryforwards $ 6,671,907 $ 6,639,882 $ 4,930,055 Stock-based compensation expense 2,936,945 4,084,595 3,220,799 Capitalized research and development costs 2,421,390 2,362,939 2,199,126 Capitalized start-up costs 1,121,802 565,530 620,016 Capitalized licensing costs 687,926 689,820 735,485 Derivative liabilities - - 6,388 Capitalized patents 288,123 273,682 235,065 Warrants 133,203 238,768 239,307 Accrued payroll 71,830 - - Contributions carryforward 2,833 2,833 2,840 Lease liabilities 26,794 - - Deferred rent - - 4,176 Deferred tax assets 14,362,753 14,858,049 12,193,257 Valuation allowance - (14,853,648 ) (12,180,021 ) Deferred tax assets 14,362,753 4,401 13,236 Deferred debt discount - - (6,388 ) Right-of-use asset (24,236 ) - - In-process research and development (24,658,231 ) - - Fixed assets (4,270 ) (4,401 ) (6,848 ) Deferred tax liabilities (24,686,737 ) (4,401 ) (13,236 ) Deferred tax assets, net $ (10,323,984 ) $ - $ - On December 31, 2022, the Successor 27,515,427 20,567,703 27,385,445 20,446,200 20,458,902 14,644,000 The Company has assessed the likelihood that deferred tax assets will be realized and considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies. A valuation allowance is established when it is “more likely than not” that all, or a portion of, deferred tax assets will not be realized. After the performance of such a review as of December 12, 2022 and December 31, 2021, management believed that uncertainty existed with respect to future realization of the Predecessor deferred tax assets and has, therefore, established full valuation allowances as of those dates. Thus, the Predecessor recorded an increase in the valuation allowance of $ 2,673,627 2,244,084 As a result of the December 12, 2022 Business Combination and the availability of new deferred tax liabilities (a) the Predecessor released its $ 14,853,648 Successor 558,581 Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2022 and 2021. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. No tax audits were commenced or were in process during the years ended December 31, 2022 and 2021 and no tax related interest or penalties were incurred during those years. The Company’s tax returns beginning with the year ended December 31, 2019 remain subject to examination.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. License Agreements L&F Research LLC On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). 351,579 648,421 March 31, 2023 500,000 January 31, 2024 30,000,000 On March 29, 2023, the Company forgave $ 351,579 648,421 65,783 331,331 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Operating Leases On January 18, 2019, the Predecessor entered into a lease agreement for approximately 3,500 89,000 497,000 The Successor 38,415 38,141 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 24,248 $ 22,028 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.84 1.84 Weighted Average Discount Rate Operating leases 6.5 % 6.5 % Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount April 1, 2023 to December 31, 2023 $ 87,054 Less: amount representing imputed interest (2,547 ) Total $ 84,507	Note 10 – Commitments and Contingencies Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. License Agreements L&F Research LLC On December 15, 2015, the Company entered into a license agreement with L&F whereby L&F granted to ZyVersa an exclusive license for certain technology, based on the terms and conditions set forth in the agreement. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee. The license agreement contains an up-front cash payment of $ 200,000 21.5 1,500,000 500,000 2,500,000 5 10 878,947 1.00 766,384 period of five years 351,579 306,411 175,789 153,324 351,578 On January 9, 2020, an amendment was entered into for the license agreement that provided for the following amendments: (i) partially extended the timing of payment of $ 1,000,000 500,000 500,000 351,579 On March 7, 2022, the Company and L&F executed a Waiver Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $ 1,500,000 On August 26, 2022, the Company and L&F executed a Waiver Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $ 1,500,000 On December 23, 2022, the Company and L&F executed a Waiver Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $ 1,500,000 See Note 13 – Subsequent Events for additional details regarding the L&F license agreement. InflamaCORE On April 18, 2019, the Company entered into a license agreement with InflamaCORE, LLC (“InflamaCORE”) whereby InflamaCORE agreed to grant the Predecessor an exclusive license to the InflamaCORE Program Technology. The term of the license agreement shall commence on the effective date and, unless earlier terminated in accordance with the terms of the agreement, continue until the expiration of the last-to-expire of all royalty payment obligations of licensee. In conjunction with this license agreement, InflamaCORE entered into an agreement with the University of Miami to aggregate all of the intellectual property and technology developed by InflamaCORE scientists, who are all employees of the University of Miami, under the InflamaCORE umbrella. The term of the agreement shall commence on the effective date and shall remain in effect until the later of (a) the date on which all issued patents and filed patent applications within the patent rights have expired or been abandoned and no royalties are due or (b) twenty (20) years, unless earlier terminated in accordance with the terms of the agreement. The two agreements were executed with the understanding that ZyVersa will further develop the intellectual property and technology under the license agreement. In consideration for the license, the Predecessor agreed to pay an up-front fee to InflamaCORE in the amount of $ 346,321 22,500,000 the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%. 1,000,000 400,000 815,822 2.30 600,000 200,000 460,000 Operating Leases On January 18, 2019, the Predecessor entered into a lease agreement for approximately 3,500 89,000 497,000 The Successor 7,795 148,881 148,125 See Note 3 – Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for information related to the Company’s adoption of the new lease accounting standard and the recognition of a right-of-use asset and operating lease liability. A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor December 31, 2022 December 12, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 4,786 $ 86,100 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1.08 1.08 Weighted Average Discount Rate Operating leases 6.5 % 6.5 % Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount Future minimum payments $ 112,916 Less: amount representing imputed interest (4,160 ) Total $ 108,756

Stockholders_ Permanent and Tem

Stockholders’ Permanent and Temporary Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Permanent and Temporary Equity	Note 8 – Stockholders’ Permanent and Temporary Equity Common Stock During the three months ended March 31, 2023, the Company entered into marketing agreements with two vendors in which the Company issued an aggregate of 130,000 395,200 Temporary Equity See Note 7 – Commitments and Contingencies for discussion of the movement of temporary equity to permanent equity on March 29, 2023. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Stock-Based Compensation For the three months ended March 31, 2023 the Successor 287,461 49,455 238,006 1,941,746 307,838 1,633,908 1,595,639 1.6 Stock Options On January 27, 2023, the Company granted ten-year 100,000 Successor 184,426 three years 2.11 On March 10, 2023, the Company granted ten-year 13,000 23,770 three years 2.26 13,000 5,000 The grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Fair value of common stock on date of grant $ 2.11 2.23 $ 3.00 Risk free interest rate 3.53 4.27 1.68 2.42 Expected term (years) 6.00 3.53 6.00 Expected volatility 120 122 111 119 Expected dividends 0.00 0.00 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements A summary of the option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 1,993,235 $ 10.81 Granted 113,000 2.13 Exercised - - Forfeited - - Outstanding, March 31, 2023 2,106,235 $ 10.35 5.6 $ - Exercisable, March 31, 2023 1,783,531 $ 10.18 5.3 $ - The following table presents information related to stock options as of March 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.11 100,000 - - $ 2.26 13,000 - - $ 5.03 662,887 2.8 662,887 $ 11.33 12,186 9.3 12,186 $ 11.58 728,430 6.0 723,576 $ 16.36 589,732 8.1 384,882 2,106,235 5.3 1,783,531 Effectiveness Failure In connection with the Business Combination, the Company issued 8,635 863,500 1,000 8,635,000 1.5 2.0 398,000 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements	Note 11 – Stockholders’ Permanent and Temporary Equity Authorized Capital The Predecessor was authorized to issue 75,000,000 0.00001 5,000,000 0.00001 The Successor 110,000,000 0.0001 1,000,000 0.0001 Equity Incentive Plans Predecessor 2014 Equity Incentive Plan The Predecessor was authorized to issue awards under its 2014 Equity Incentive Plan (the “2014 Plan”), as amended on October 9, 2018, February 2, 2019 and February 2, 2021. Under the 2014 Plan, 10,000,000 The number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2014 Plan, beginning with calendar year 2019, by an amount equal to five percent (5%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year, but in no event shall any such annual increase exceed 100,000 shares of common stock. 45,652 On December 12, 2022, in connection with the consummation of the Business Combination, the Predecessor approved the amendment to the 2014 Plan (the “2014 Plan Amendment”). The 2014 Plan Amendment provides, among other things, that upon consummation of the Business Combination, no further increases in the shares of common stock reserved and available for issuance under the 2014 Plan shall occur and no new awards shall be made under the 2014 Plan. Successor 2022 Omnibus Equity Incentive Plan The Successor is authorized to issue awards under the 2022 Omnibus Equity Incentive Plan (the “2022 Plan”). Under the 2022 Plan, 1,089,831 1,089,831 Successor Redeemable Common Stock On December 13, 2020 (the “Effective Date”), in connection with the L&F Note Agreement (see Note 5 – Note Receivable for details), the Predecessor and L&F entered into an agreement to provide L&F with a put option to cause the Company to purchase up to 331,331 1.00 331 On December 12, 2022, the Company closed on the Business Combination (see Note 4 – Business Combination) whereby the 331,331 65,783 5.04 See Note 13 – Subsequent Events for additional details regarding the L&F Note and the Put Option. Predecessor Series A Preferred Stock Predecessor Series A Preferred Stock Financing On March 31, 2022, the Predecessor sold 133,541 3.14 392,301 100,000 The Predecessor Series A Preferred Stock is convertible, at the option of the holder, at any time into shares of Predecessor common stock on a one-to-one basis, subject to standard antidilution adjustments. In addition, in the event of any non-exempt issuances by the Company for less than the in-force conversion price, the Predecessor Series A Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Predecessor Series A Preferred Stock shall automatically be converted into shares of Predecessor common stock at the then effective conversion price concurrently with (i) the closing of a Public Transaction or (ii) the date specified by written consent or agreement of the holders of a majority of the then outstanding shares of Predecessor Series A Preferred stock. A Public Transaction represents either (a) a firm commitment underwritten public offering; or (b) the closing of a transaction with a special purpose acquisition company (“SPAC”) listed on the Nasdaq Stock Market in which the Company would become a wholly owned subsidiary of the SPAC. The Predecessor Series A Preferred stockholders shall vote together with the Predecessor common stockholders on an as-converted basis and dividends will only be paid on an as-converted basis when, and if paid to Predecessor common stockholders. In the event of any liquidation, dissolution or winding up of the Predecessor or upon a Deemed Liquidation Event, the Predecessor Series A Preferred stockholders will be entitled to be paid, out of the assets of the Predecessor available for distribution before any payments are made to Predecessor common stockholders, one times the original purchase price, plus declared and unpaid dividends on each share of Predecessor Series A Preferred Stock or, if greater, the amount that the Predecessor Series A Preferred Stock holders would receive on an as-converted basis. The balance of any proceeds shall be distributed pro rata to the Predecessor common stockholders. Deemed Liquidation Events include (a) a merger or consolidation in which the Predecessor or a subsidiary thereof is a constituent party which results in a change-of-control (a “Merger Event”); or (b) the sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Predecessor (a “Disposition Event”). The Predecessor Series A Preferred Stock is not mandatorily redeemable and therefore it is not subject to classification as a liability. The Predecessor determined that the Deemed Liquidation Events were within the control of the Predecessor and, therefore, the Predecessor Series A Preferred Stock should be classified as permanent equity. Specifically, Merger Events and Disposition Events require the approval of the board of directors pursuant to state law and the Predecessor preferred stockholders are unable to control the vote of the board of directors. The Predecessor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Predecessor will need to assess the accounting for the price reset. Due to the Predecessor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. On July 8, 2022, the Predecessor sold an additional 94,393 3.14 296,400 21,200 On September 16, 2022, the Predecessor sold an additional 222,929 3.14 700,000 16,000 On December 6, 2022, the Predecessor sold an additional 174,776 3.14 548,805 2,000 Amendment of Predecessor Series A Preferred Stock Designation On May 10, 2022, the Predecessor obtained the requisite approvals to (a) amend the Predecessor Series A Preferred Stock Designation within the Predecessor’s Certificate of Incorporation to reduce the effective conversion price of the Predecessor Series A Preferred Stock from $ 3.14 2.78 3.20 331,200 Second Amendment of Predecessor Series A Preferred Stock Designation On August 31, 2022, the Predecessor filed with the Florida Department of State a second amendment to the Predecessor Series A Preferred Stock Designation within the Predecessor’s Certificate of Incorporation, which reduced the conversion price of the Predecessor Series A Preferred Stock from $ 2.78 per share of Predecessor common stock and Predecessor Series A Warrant to $ 1.19 per share of Predecessor common stock and Predecessor Series A Warrant. In addition, the Predecessor reduced the exercise price of the Predecessor Series A Warrants issuable at conversion from $ 3.20 per share to $ 1.37 per share. The Predecessor determined that the reduction of the Predecessor Series A Preferred Stock conversion price, combined with the revised terms associated with the Predecessor Series A Warrants (collectively the “Second Amendment Securities”) issuable at conversion, represented a significant change requiring the application of extinguishment accounting. Accordingly, it was necessary to record the $ 9,684,637 Extinguishments of Predecessor Series A Preferred Stock The Company determined that the reduction of the Series A Preferred Stock conversion price, combined with the contingent issuance of the Series A Warrants or the change in the (collectively the “Amended Securities”), represented a significant change requiring the application of extinguishment accounting. Accordingly, it was necessary to record the $ 331,200 Automatic Conversion of Predecessor Series A Preferred Stock On December 12, 2022, in connection with the Business Combination, all outstanding 2,427,832 6,406,210 6,406,210 1,271,904 1,271,904 6.90 Successor Preferred Stock Successor Series A Preferred Stock Financing In connection with the Business Combination, the Successor 8,635 863,500 11.50 1,000 8,635,000 The Successor Series A Preferred Stock is convertible, at the option of the holder, at any time into a number of shares of Successor common stock equal to the face value divided by the conversion price then in effect (initially $10.00). In addition, for five years following the issuance of the Successor Series A Preferred Stock, the conversion price is automatically adjusted to the greater of (a) $2.00; and (b) the lowest price of any subsequent offerings of securities at a price less than the conversion price. The conversion price also resets at both 90 days and 150 days following the effectiveness of the registration of the Successor Series A Preferred Stock (each a “Commencement Date”) to the greater of (a) $2.00; and (b) 85% of the lowest of the ten consecutive daily volume-weighted average prices commencing on, and including, each Commencement Date. As of the filing date, the Successor Series A Preferred Stock has not been registered and no conversion price reset has occurred. The Successor Series A Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to Successor common stockholders. In the event of any liquidation, dissolution or winding up of the Successor, each Successor Series A Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Successor Series A Preferred stockholders on an as-converted basis pari passu The Successor Series A Preferred Stock is not redeemable at the election of the holder and, therefore, it is classified as permanent equity. However, subject to the holder’s right to elect to convert, the Company has the right to redeem the Successor Series A Preferred Stock anytime at 120% of the face value. The Successor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Company will need to assess the accounting for the price reset. Due to the Successor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. Successor Preferred Series B Issuance In connection with the Business Combination, the Successor 5,062 1,000 5,062,000 The Successor 10.00 The conversion price also resets at 150 days following the effectiveness of the registration of the Successor 7.00 The Successor Series B Preferred stockholders have no voting rights and dividends will only be paid on an as-converted basis when, and if paid to Successor common stockholders. In the event of any liquidation, dissolution or winding up of the Successor each Successor Series B Preferred stockholder shall be entitled to be paid out of the assets of the Company legally available for distribution, the stated value of their holdings, plus any accrued and unpaid dividends. The balance of any proceeds shall be distributed to Successor Series B Preferred stockholders on an as-converted basis pari passu The Successor Series B Preferred Stock is not redeemable and, therefore, it is classified as permanent equity. The Successor determined that the embedded conversion options were clearly and closely related to the preferred stock host and, therefore, the embedded conversion options need not be bifurcated. However, if the conversion price is reset in connection with a subsequent issuance of securities, the Successor will need to assess the accounting for the price reset. Due to the Successor’s adoption of ASU 2020-06 on January 1, 2021, it wasn’t necessary to assess the embedded conversion options for a beneficial conversion feature. Stock-Based Compensation For the period December 13, 2022 through December 31, 2022, the Successor 56,333 7,808 48,525 3,524,802 673,160 2,851,642 2,957,047 1.6 For the year ended December 31, 2021, the Company recorded stock-based compensation expense of $ 4,245,463 944,525 3,300,938 Stock Options On December 12, 2022, the Company closed on the Business Combination (see Note 4 – Business Combination) whereby the 10,039,348 1,993,235 Successor 5.037 In applying the Black-Scholes option pricing model to Predecessor stock options granted, the Company used the following assumptions: Schedule of Stock Options Granted Successor Predecessor Predecessor Successor Predecessor For the period For the period For the year December 13 through January 1 through ended December 31, 2022 December 12, 2022 December 31, 2021 Fair value of common stock on date of grant n/a $ 2.27 3.00 $ 3.25 Risk free interest rate n/a 1.68 3.01 % 0.66 1.26 % Expected term (years) n/a 3.53 6.00 5.00 6.00 Expected volatility n/a 111 119 % 118 125 % Expected dividends n/a 0.00 % 0.00 % During the period ended December 12, 2022, the fair value of the Predecessor’s common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Company valuation of $ 85 During the year ended December 31, 2021, the fair value of the Predecessor’s common stock was determined by management with the assistance of a third-party valuation specialist using an income approach. The options granted during the year ended December 31, 2021 had a contractual term of ten years and a requisite service period of zero to three years. A summary of the option activity for the period December 13, 2022 through December 31, 2022 for the Successor and the period ended December 12, 2022 for the Predecessor is presented below: Schedule of Stock Option Activity Successor Number of Options Weighted Average Exercise Price Weighted Average Remaining Life In Years Aggregate Intrinsic Value Outstanding, December 13, 2022 1,993,235 $ 10.81 Granted - - Exercised - - Forfeited - - Outstanding, December 31, 2022 1,993,235 $ 10.81 5.8 $ - Exercisable, December 31, 2022 1,639,566 $ 9.63 5.3 $ - Predecessor Number of Options Weighted Average Exercise Price Weighted Average Remaining Life In Years Aggregate Intrinsic Value Outstanding, January 1, 2022 8,755,179 $ 2.00 Granted 1,284,169 3.17 Exercised - - Forfeited - - Outstanding, December 12, 2022 10,039,348 $ 2.15 5.9 $ 3,271,992 Exercisable, December 12, 2022 8,258,023 $ 1.91 5.3 $ 3,271,992 The following table presents information related to stock options as of December 31, 2022: Schedule of Information Related to Stock Options Successor Options Outstanding Options Exercisable Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.03 662,887 3.1 662,887 $ 11.33 12,186 9.5 12,186 $ 11.58 728,430 6.3 723,576 $ 16.36 589,732 8.3 240,917 1,993,235 5.3 1,639,566 Stock Warrants A summary of the warrant activity for the period December 13, 2022 through December 31, 2022 for the Successor and the period ending December 12, 2022 for the Predecessor is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Successor Warrants Price In Years Value Outstanding, December 13, 2022 8,628,706 $ 10.75 Issued - - Outstanding, December 31, 2022 8,628,706 $ 10.75 4.8 $ - Exercisable, December 31, 2022 8,558,904 $ 10.79 4.8 $ - Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Predecessor Warrants Price In Years Value Outstanding, January 1, 2022 2,154,352 $ 1.98 Issued 6,406,210 1.37 Exercised - - Outstanding, December 12, 2022 8,560,562 $ 1.52 1.8 $ 59,681 Exercisable, December 12, 2022 8,560,562 $ 1.55 3.9 $ 34,203 The following table presents information related to stock warrants as of December 31, 2022 for the Successor: Schedule of Information Related to Stock Warrants Successor Warrants Outstanding Warrants Exercisable Exercise Outstanding Weighted Average Exercisable Number of Price Number of Remaining Life Warrants $ 5.03 104,704 2.0 34,901 $ 6.90 1,271,904 4.9 1,271,904 $ 11.50 6,929,073 4.9 6,929,073 $ 11.58 323,026 1.0 323,026 8,628,706 4.8 8,558,904 The Successor stock warrants at December 31, 2022, consist of the following: (a) Exercisable warrants to purchase 6,065,573 Successor 11.50 0.01 18.00 (b) Exercisable warrants to purchase 863,500 Successor 11.50 (c) Warrants to purchase 1,699,633 Successor 8,560,561 5.037 Successor 5.037 The Replacement Warrants include (a) exercisable warrants to purchase 1,271,904 shares of Successor common stock with an exercise price of $6.90 per share and with an expiration date of December 12, 2027, which replace the warrants that were issued by the Predecessor to its Series A Preferred Stock holders upon the automatic conversion of their Predecessor Series A Preferred Stock into Predecessor common stock and Predecessor Series A Warrants upon the closing of the Business Combination (see Note 11 – Stockholders’ Permanent and Temporary Equity – Automatic Conversion of Predecessor Series A Preferred Stock); (b) warrants to purchase 104,704 shares of Successor common stock with an exercise price of $5.03 per share which replace the warrants that were issued by the Predecessor to a strategic partner (see Note 10 – Commitments and Contingencies – License Agreements – L&F Research LLC), of which warrants to purchase 34,901 shares are exercisable until they expire on or about January 6, 2025, while the remainder vest upon the achievement of certain milestones and expire five years following the achievement of those milestones; and (c) exercisable warrants to purchase 323,026 shares of Successor common stock with an exercise price of $11.58 per share and with various expiration dates through April 17, 2024 which replace the warrants that were issued by the Predecessor to certain purchasers of convertible notes, certain brokers and a strategic partner in conjunction with entering into a license agreement (see Note 10 – Commitments and Contingencies – License Agreements – InflamaCORE).

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events Equity Offering On April 28, 2023, the Company completed an offering of 11,015,500 11,015,500 11.0 1.00 0.5 0.4 As a result of the Registered Offering, the conversion price of the 5,062 7.00 863,500 2.00 4,965,125 Redemption of PIPE Shares The proceeds from the Registered Offering were used to redeem substantially all of the original PIPE Shares for a purchase price of $ 10.1 20% 1.7 0.4 0.2 2.00 Stock Options On May 24, 2023, the Company granted ten-year 1,453,107 0.44 150,000 three years Private Placement On June 5, 2023, the Company issued 3,044,152 Stock Issuance On May 19, 2023, the Company issued 380,000	Note 13 – Subsequent Events The Company has evaluated subsequent events through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as discussed below. License Agreements On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $1,500,000 of milestone payments, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (‘Waiver B”). 351,579 648,421 March 31, 2023 500,000 January 31, 2024 30,000,000 On March 29, 2023, the Company paid the $ 648,421 Stock Option Grants On January 27, 2023, the Company granted ten-year stock options to purchase 100,000 Successor 2.11 On March 10, 2023, the Company granted ten-year stock options to purchase 13,000 2.26 13,000 5,000 Effectiveness Failure On or about February 20, 2023, the Company failed to have the SEC declare a registration statement effective (the “Effectiveness Failure”) which covered the PIPE registrable securities within the time period prescribed by the PIPE Securities Purchase Agreement (the “SPA”). The SPA entitles the PIPE investors to receive Registration Delay Payments equal to 1.5% of each investor’s purchase price on the date of the Effectiveness Failure and every thirty days thereafter that the Effectiveness Failure persists. Failure to make the Registration Delay Payments on a timely basis results in the accrual of interest at the rate of 2.0 260,000

Business Combination

Business Combination	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination	Note 4 – Business Combination On July 20, 2022, the Operating Company entered into a Business Combination Agreement, (the “Business Combination Agreement”), with Larkspur, Larkspur Merger Sub Inc. (“Merger Sub” a wholly owned subsidiary of Larkspur) and Stephen Glover, in his capacity as the representative of the shareholders of the Operating Company. Larkspur was a blank-check special purpose acquisition company (“SPAC”) that became a public company as a result of completing its initial public offering on December 23, 2021 and it was formed for the purpose of effecting a combination with a private company business that could benefit by gaining access to the capital that can be raised because its shares are publicly traded on Nasdaq. On December 12, 2022, the Business Combination was consummated following a special meeting of stockholders on December 8, 2022, where the stockholders of Larkspur, considered and approved, among other matters, a proposal to adopt the Business Combination Agreement. Further information regarding the Business Combination is set forth in (i) the proxy statement / prospectus included in the registration statement on Form S-4 (File No. 333-266838), as amended and supplemented, originally filed with the SEC on August 12, 2022 and declared effective by the SEC on November 14, 2022; and (ii) the Current Report on Form 8-K filed with the SEC on July 22, 2022. The Business Combination included the following transactions: ● The Operating Company merged into Merger Sub with the result that the Operating Company was the surviving entity and incorporated in Delaware. ● The Operating Company’s common stockholders exchanged their 33,845,335 33,514,004 331,331 6,719,730 Successor 5.037 ● The 10,039,348 1,993,235 5.037 ● The 8,560,561 1,699,633 5.037 The Company accounted for the Business Combination as a forward acquisition of the Operating Company as it was determined that the Operating Company was a variable interest entity as of the date of the Business Combination. The New Parent is the primary beneficiary as its ownership provides the power to direct the activities of the Operating Company and the obligation to absorb the losses and/or receive the benefits of the Operating Company. The Business Combination was recorded using the acquisition method of accounting and the initial purchase price allocation was based on our preliminary assessment of the fair value of the purchase consideration and the fair value of the Operating Company’s tangible and intangible assets acquired and liabilities assumed at the date of acquisition. The purchase price allocation is not complete due to the proximity of the acquisition date to calendar year end and will be refined during the permitted twelve-month measurement period. The preliminary estimates of the acquisition-date fair value of the purchase consideration were estimated using a market approach with Level 1 inputs (observable inputs) in the case of the fair value of the Successor’s common stock and Level 3 inputs (unobservable inputs) in the case of the fair value attributed to the Successor warrants and options. The acquiror was obligated to replace the Operating Company’s existing warrants and options pursuant to the Business Combination Agreement. Accordingly, it was necessary to allocate the fair value of the replacement warrants and options between purchase consideration (the fair value attributable to pre-combination services) and compensation for post-combination services. The fair value of the replacement warrants and options attributable to post-combination services was $ 584,260 1,731,237 The preliminary estimates of the acquisition-date fair value of the purchase consideration were as follows: Schedule of Fair Value of the Purchase Consideration Successor common stock $ 67,197,300 Successor warrants 12,190,015 Successor options 11,864,556 Total fair value of the purchase consideration $ 91,251,871 The preliminary acquisition-date fair values of the assets acquired were estimated by management, but will eventually be refined and, especially for the in-process research and development, will include estimates using an income approach. The excess of the purchase price over the estimated fair values of the identifiable net assets acquired was recorded as goodwill. Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill Current assets, including cash of $ 699,324 $ 1,093,223 In-process research and development 100,086,329 Goodwill 11,895,033 Other non-current assets 64,523 Total assets acquired 113,139,108 Current liabilities 10,818,204 Deferred tax liabilities 11,069,033 Total assumed liabilities 21,887,237 Net assets acquired $ 91,251,871 In-process research and development recorded for book purposes is considered an indefinite-lived intangible asset until the completion or the abandonment of the research and development efforts. Because the acquisition was structured as a stock sale, the in-process research and development and the goodwill is not expected to have any tax basis and isn’t expected to be deductible for tax purposes. The Predecessor incurred approximately $ 2.1 Given the non-recurring nature of Larkspur’s activities as a SPAC, pro forma financial data combining the pre-Business Combination results of both Larkspur and the Operating Company would not be meaningful and have not been presented. The Successor sold Series A Preferred Stock for net proceeds of $ 8,635,000

Note Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2022
Note Receivable
Note Receivable	Note 5 – Note Receivable On December 13, 2020, the Company and L&F entered into a promissory note agreement (“L&F Note Agreement”) whereby the Company agreed to accept a note receivable in the principal amount of $ 351,579 1.17 L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $ 500,000 6,000

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable Unsecured Convertible Promissory Notes Between October 2019 and July 2020, the Company issued 24-month Unsecured Convertible Promissory Notes (“the Notes”) to investors and brokers in the aggregate principal amount of $ 3,961,000 25,000 6 20 20 20 3.25 80 3.25 373,000 64,342 During February and March 2021, the Company issued new Unsecured Convertible Promissory Notes (“2021 Notes”) with an aggregate principal balance of $ 5,230,000 3,150,000 6 500,000 3.25 The Company analyzed the embedded features of the 2021 Notes and determined that the 2021 Notes contained (i) an automatic conversion upon a Qualified Debt Financing which did not require bifurcation, (ii) an automatic conversion upon a Qualified Equity Financing at a fixed price of $3.25 per share which did not require bifurcation, (iii) an automatic conversion upon a Change of Control at a fixed price of $3.25 per share which did not require bifurcation, and (iv) a redemption feature upon default which did not require bifurcation. During January 2022, the Company and its convertible note holders agreed to extend the maturity of the Notes and the 2021 Notes to December 31, 2022. The extensions qualified as modifications because the terms were not substantially different. Accordingly, the extended notes were treated as a continuation of the original Notes and 2021 Notes. The Company is required to pay a cash fee equal to 8 228,236 For the period December 13, 2022 through December 31, 2022 the Successor 0 During the periods ended December 12, 2022 and December 31, 2021, the Predecessor recorded amortization of debt discount as interest expense in the statements of operations of $ 709,608 317,833 Automatic Conversion On July 8, 2022, as a result of an additional Predecessor Series A Preferred Stock financing (which resulted in a Qualified Equity Financing with cumulative gross proceeds that exceeded $ 500,000 5,230,000 428,888 1,802,193 3.14 On December 12, 2022, the Company closed on the Business Combination (see Note 4 – Business Combination) which met the legal definition of a reverse merger with a publicly traded company (albeit for accounting purposes it was a forward merger). Accordingly, such Business Combination met the definition of a Qualified Offering and, as such, the $ 3,961,000 709,608 1,167,601 2,940,537 583,831 The automatic conversion was pursuant to the share-settled redemption feature included in the original terms of the Notes which resulted in a conversion price of $ 1.58835 80 1.98542

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 12 – Related Party Transactions During the period December 13, 2022 through December 31, 2022, the Successor had no related party transactions. During the periods ended December 12, 2022 and December 31, 2021, the Predecessor paid $ 0 50,000 During the periods ended December 12, 2022 and 2021, the Company received $ 0 3,150,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 4,101,625 shares if the Successor Series A warrant exercise price resets to its floor price of $ 2.00 per share. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements	Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor December 31, 2022 December 12, 2022 December 31, 2021 Predecessor warrants [1] - 8,560,561 2,154,351 Successor warrants [1] [5] 8,628,695 - - Predecessor options - 10,039,348 8,755,179 Successor options 1,993,235 - - Predecessor Series A Convertible Preferred Stock - 6,406,210 - Successor Series A Convertible Preferred Stock 863,500 (3) - - Successor Series B Convertible Preferred Stock 506,264 (4) - - Predecessor convertible notes payable [2] - - 3,400,187 Total potentially dilutive shares 11,991,694 25,006,119 14,309,717 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.25 [3] Does not include an additional 3,454,000 [4] Does not include an additional 216,970 [5] Does not include an additional 3,454,000
Segment Reporting	Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.	Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Basis of Presentation and Principles of Consolidation		Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the consolidated financial statements. The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the accounting rules and regulations of the United States Securities and Exchange Commission (“SEC”).
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2022 and 2021, the Company had no cash equivalents. The Company has cash deposits which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. See Note 1 – Risks and Uncertainties.
Business Combination		Business Combination In applying the acquisition method of accounting for business combinations, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Intangible assets are initially valued at fair value using generally accepted valuation methods appropriate for the type of intangible asset. In-process research and development (IPR&D) acquired in a business combination is capitalized as an indefinite-lived intangible asset until regulatory approval is obtained, at which time it is accounted for as a definite-lived asset and amortized over its estimated useful life, or discontinuation, at which point the intangible asset will be written off.
Long-Lived Assets and Goodwill		Long-Lived Assets and Goodwill The Company accounts for long-lived assets in accordance with the provisions of ASC 360-10-35, Property, Plant and Equipment, Impairment or Disposal of Long-lived Assets The Company accounts for goodwill and intangible assets in accordance with ASC 350, Intangibles – Goodwill and Other In determining whether a quantitative assessment is required, the Company will evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after performing the qualitative assessment, an entity concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the entity would perform the quantitative impairment test described in ASC 350. However, if, after applying the qualitative assessment, the entity concludes that it is not more than likely that the fair value is less than the carrying amount, the quantitative impairment test is not required. The Company bases these assumptions on its historical data and experience, industry projections, micro and macro general economic condition projections, and its expectations.
Equipment, Net		Equipment, Net Equipment is stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight- line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which is 5 52,000 34,667 24,267 Successor 532 Predecessor 9,869
Financing Costs		Financing Costs Debt issuance costs, which primarily consist of direct, incremental professional fees incurred in connection with a debt financing, are reported as a direct deduction from the face amount of the notes payable and are amortized over the contractual term of the underlying notes payable using the effective interest method.
Convertible Promissory Notes		Convertible Promissory Notes The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 “Derivatives and Hedging” (“ASC 815”) of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The accounting treatment of derivative financial instruments requires that the Company record any bifurcated embedded features at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded in earnings each period as non-operating, non-cash income or expense. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Bifurcated embedded features are recorded at their initial fair values which create additional debt discount to the host instrument. Prior to the January 1, 2021 adoption of Accounting Standards Update (“ASU”) 2020-06, if the embedded conversion options did not require bifurcation, the Company then evaluated for the existence of a beneficial conversion feature by comparing the fair value of the Company’s underlying stock as of the commitment date to the effective conversion price of the instrument (the intrinsic value). The host instrument is measured at amortized cost with the carrying value being accreted to the stated principal amount of contractual maturity using the effective-interest method with a corresponding charge to interest expense. After the January 1, 2021 adoption of ASU 2020-06, the Company is no longer required to evaluate for the existence of a beneficial conversion feature.
Fair Value of Financial Instruments		Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable; and Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions). The carrying amounts of the Company’s financial instruments, such as cash, accounts payable and investor deposits approximate fair values due to the short-term nature of these instruments. See Note 8 – Derivative Liabilities for additional details regarding the valuation technique and assumptions used in valuing Level 3 inputs.
Income Taxes		Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date. The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
Leases		Leases See Note 3 - Summary of Significant Accounting Policies – Recently Adopted Accounting Pronouncements for further details on the adoption of ASC 842.
Research and Development		Research and Development Research and development expenses are charged to operations as incurred.
Stock-Based Compensation		Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
Fair Value of Stock Options and Warrants		Fair Value of Stock Options and Warrants The Company has computed the fair value of stock options and warrants granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. Successor common stock will be valued using the market approach using the trading prices of the common stock on the Nasdaq Global Market. During 2022, the fair value of the Predecessor common stock was determined using a market approach based on the status of the business combination agreement arm’s length discussions with the acquirer at each valuation date and which agreement was ultimately entered into on July 20, 2022 with a Predecessor valuation of $ 85
Recently Adopted Accounting Pronouncements		Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s financial statements. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Companies should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. This standard was adopted on January 1, 2022 and did not have a material impact on the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to clarify the accounting for certain financial instruments with characteristics of liabilities and equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock by removing the cash conversion model and the beneficial conversion feature model. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in-capital. In addition, this ASU improves disclosure requirements for convertible instruments and earnings-per-share guidance. The ASU also revises the derivative scope exception guidance to reduce form-over-substance-based accounting conclusions driven by remote contingent events. The amendments in this update are effective for our fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption will be permitted, but no earlier than for fiscal years beginning after December 15, 2020. The Company early adopted ASU 2020-06 effective January 1, 2021 which eliminated the need to assess whether a beneficial conversion feature needs to be recognized upon the issuance of new convertible instruments. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842).” ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for private companies and emerging growth companies for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” and ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company adopted ASU 2016-02 on December 31, 2022, effective January 1, 2022 and the adoption of this ASU resulted in the recording of right-of-use assets and lease liabilities for the Company’s operating leases in the approximate amounts of $ 182,732 199,642 16,910
Reclassifications		Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 4,101,625 shares if the Successor Series A warrant exercise price resets to its floor price of $ 2.00 per share.	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor December 31, 2022 December 12, 2022 December 31, 2021 Predecessor warrants [1] - 8,560,561 2,154,351 Successor warrants [1] [5] 8,628,695 - - Predecessor options - 10,039,348 8,755,179 Successor options 1,993,235 - - Predecessor Series A Convertible Preferred Stock - 6,406,210 - Successor Series A Convertible Preferred Stock 863,500 (3) - - Successor Series B Convertible Preferred Stock 506,264 (4) - - Predecessor convertible notes payable [2] - - 3,400,187 Total potentially dilutive shares 11,991,694 25,006,119 14,309,717 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.25 [3] Does not include an additional 3,454,000 [4] Does not include an additional 216,970 [5] Does not include an additional 3,454,000

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 291,552 584,226 Other accrued expenses 51,968 214,229 Federal income tax payable 106,683 106,683 Bonus accrual 764,590 - Registration delay liability [2] 398,019 - Accrued interest Deferred rent Total accrued expenses and other current liabilities $ 2,112,812 $ 2,053,559 [1] See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note. [2] See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.	As of December 31, 2022 and 2021, accrued expenses and other current liabilities consisted of the following: Schedule of Accrued Expenses and Other Current Liabilities 2022 2021 For the Years Ended December 31, 2022 2021 L&F milestone payment liability $ 1,500,000 $ 1,500,000 L&F Note (351,579 ) (351,579 ) L&F, net 1,148,421 1,148,421 Payroll accrual 584,226 - Other accrued expenses 214,229 - Federal income tax payable 106,683 - Accrued interest - 748,767 Deferred rent - 16,913 Total accrued expenses and other current liabilities $ 2,053,559 $ 1,914,101

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate	Income tax expense and the effective tax rate were as follows: Schedule of Income Tax Expense and the Effective Tax Rate Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, (in thousands) 2023 2022 Income tax benefit $ 1,047,051 $ - Effective tax rate 22.81 % 0.00 %	The provision for income taxes differs from the Federal statutory rate as follows: Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor For the period For the period December 13 through January 1 through For the year ended December 31, 2022 December 12, 2022 December 31, 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % State tax rate, net of federal benefit 3.6 % 3.6 % 3.7 % Permanent items (1.9 %) (5.4 %) (0.9 %) Nondeductible basis difference 0.0 % 0.0 % 0.1 % Effect of change in state rate 0.0 % (0.1 %) 3.9 % Prior period adjustments and other 0.0 % (0.1 %) 0.0 % Change in valuation allowance 68.1 % (19.0 %) (27.8 %) Effective income tax rate 90.8 % (0.0 %) 0.0 %
Schedule of Provision For Income Taxes		The provision for income taxes consists of the following (benefits) provisions: Schedule of Provision For Income Taxes December 31, 2022 December 12, 2022 December 31, 2021 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Successor Predecessor For the period For the period December 13 through January 1 For the year December 31, 2022 December 12, 2022 December 31, 2021 Deferred tax benefit: Federal $ (151,625 ) $ (2,191,344 ) $ (1,480,472 ) State (34,844 ) (482,283 ) (763,612 ) Deferred tax benefit (186,469 ) (2,673,627 ) (2,244,084 ) Change in valuation allowance (558,581 ) 2,673,627 2,244,084 Provision for income taxes $ (745,050 ) $ - $ -
Schedule of Deferred Tax Assets and Liabilities		Deferred tax assets and liabilities consist of the following: Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 12, 2022 December 31, 2021 Successor Predecessor Predecessor Successor Predecessor December 31, 2022 December 12, 2022 December 31, 2021 Net operating loss carryforwards $ 6,671,907 $ 6,639,882 $ 4,930,055 Stock-based compensation expense 2,936,945 4,084,595 3,220,799 Capitalized research and development costs 2,421,390 2,362,939 2,199,126 Capitalized start-up costs 1,121,802 565,530 620,016 Capitalized licensing costs 687,926 689,820 735,485 Derivative liabilities - - 6,388 Capitalized patents 288,123 273,682 235,065 Warrants 133,203 238,768 239,307 Accrued payroll 71,830 - - Contributions carryforward 2,833 2,833 2,840 Lease liabilities 26,794 - - Deferred rent - - 4,176 Deferred tax assets 14,362,753 14,858,049 12,193,257 Valuation allowance - (14,853,648 ) (12,180,021 ) Deferred tax assets 14,362,753 4,401 13,236 Deferred debt discount - - (6,388 ) Right-of-use asset (24,236 ) - - In-process research and development (24,658,231 ) - - Fixed assets (4,270 ) (4,401 ) (6,848 ) Deferred tax liabilities (24,686,737 ) (4,401 ) (13,236 ) Deferred tax assets, net $ (10,323,984 ) $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right of Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 24,248 $ 22,028 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.84 1.84 Weighted Average Discount Rate Operating leases 6.5 % 6.5 %	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor December 31, 2022 December 12, 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 4,786 $ 86,100 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1.08 1.08 Weighted Average Discount Rate Operating leases 6.5 % 6.5 %
Schedule of Future Minimum Payments Under Lease	Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount April 1, 2023 to December 31, 2023 $ 87,054 Less: amount representing imputed interest (2,547 ) Total $ 84,507	Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount Future minimum payments $ 112,916 Less: amount representing imputed interest (4,160 ) Total $ 108,756

Stockholders_ Permanent and T_2

Stockholders’ Permanent and Temporary Equity (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Schedule of Stock Options Granted	The grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Fair value of common stock on date of grant $ 2.11 2.23 $ 3.00 Risk free interest rate 3.53 4.27 1.68 2.42 Expected term (years) 6.00 3.53 6.00 Expected volatility 120 122 111 119 Expected dividends 0.00 0.00	In applying the Black-Scholes option pricing model to Predecessor stock options granted, the Company used the following assumptions: Schedule of Stock Options Granted Successor Predecessor Predecessor Successor Predecessor For the period For the period For the year December 13 through January 1 through ended December 31, 2022 December 12, 2022 December 31, 2021 Fair value of common stock on date of grant n/a $ 2.27 3.00 $ 3.25 Risk free interest rate n/a 1.68 3.01 % 0.66 1.26 % Expected term (years) n/a 3.53 6.00 5.00 6.00 Expected volatility n/a 111 119 % 118 125 % Expected dividends n/a 0.00 % 0.00 %
Schedule of Stock Option Activity	A summary of the option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 1,993,235 $ 10.81 Granted 113,000 2.13 Exercised - - Forfeited - - Outstanding, March 31, 2023 2,106,235 $ 10.35 5.6 $ - Exercisable, March 31, 2023 1,783,531 $ 10.18 5.3 $ -	A summary of the option activity for the period December 13, 2022 through December 31, 2022 for the Successor and the period ended December 12, 2022 for the Predecessor is presented below: Schedule of Stock Option Activity Successor Number of Options Weighted Average Exercise Price Weighted Average Remaining Life In Years Aggregate Intrinsic Value Outstanding, December 13, 2022 1,993,235 $ 10.81 Granted - - Exercised - - Forfeited - - Outstanding, December 31, 2022 1,993,235 $ 10.81 5.8 $ - Exercisable, December 31, 2022 1,639,566 $ 9.63 5.3 $ - Predecessor Number of Options Weighted Average Exercise Price Weighted Average Remaining Life In Years Aggregate Intrinsic Value Outstanding, January 1, 2022 8,755,179 $ 2.00 Granted 1,284,169 3.17 Exercised - - Forfeited - - Outstanding, December 12, 2022 10,039,348 $ 2.15 5.9 $ 3,271,992 Exercisable, December 12, 2022 8,258,023 $ 1.91 5.3 $ 3,271,992
Schedule of Information Related to Stock Options	The following table presents information related to stock options as of March 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.11 100,000 - - $ 2.26 13,000 - - $ 5.03 662,887 2.8 662,887 $ 11.33 12,186 9.3 12,186 $ 11.58 728,430 6.0 723,576 $ 16.36 589,732 8.1 384,882 2,106,235 5.3 1,783,531	The following table presents information related to stock options as of December 31, 2022: Schedule of Information Related to Stock Options Successor Options Outstanding Options Exercisable Outstanding Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.03 662,887 3.1 662,887 $ 11.33 12,186 9.5 12,186 $ 11.58 728,430 6.3 723,576 $ 16.36 589,732 8.3 240,917 1,993,235 5.3 1,639,566
Summary of Warrant Activity		A summary of the warrant activity for the period December 13, 2022 through December 31, 2022 for the Successor and the period ending December 12, 2022 for the Predecessor is presented below: Summary of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Successor Warrants Price In Years Value Outstanding, December 13, 2022 8,628,706 $ 10.75 Issued - - Outstanding, December 31, 2022 8,628,706 $ 10.75 4.8 $ - Exercisable, December 31, 2022 8,558,904 $ 10.79 4.8 $ - Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Predecessor Warrants Price In Years Value Outstanding, January 1, 2022 2,154,352 $ 1.98 Issued 6,406,210 1.37 Exercised - - Outstanding, December 12, 2022 8,560,562 $ 1.52 1.8 $ 59,681 Exercisable, December 12, 2022 8,560,562 $ 1.55 3.9 $ 34,203
Schedule of Information Related to Stock Warrants		The following table presents information related to stock warrants as of December 31, 2022 for the Successor: Schedule of Information Related to Stock Warrants Successor Warrants Outstanding Warrants Exercisable Exercise Outstanding Weighted Average Exercisable Number of Price Number of Remaining Life Warrants $ 5.03 104,704 2.0 34,901 $ 6.90 1,271,904 4.9 1,271,904 $ 11.50 6,929,073 4.9 6,929,073 $ 11.58 323,026 1.0 323,026 8,628,706 4.8 8,558,904

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Fair Value of the Purchase Consideration	The preliminary estimates of the acquisition-date fair value of the purchase consideration were as follows: Schedule of Fair Value of the Purchase Consideration Successor common stock $ 67,197,300 Successor warrants 12,190,015 Successor options 11,864,556 Total fair value of the purchase consideration $ 91,251,871
Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill	Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill Current assets, including cash of $ 699,324 $ 1,093,223 In-process research and development 100,086,329 Goodwill 11,895,033 Other non-current assets 64,523 Total assets acquired 113,139,108 Current liabilities 10,818,204 Deferred tax liabilities 11,069,033 Total assumed liabilities 21,887,237 Net assets acquired $ 91,251,871

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Changes in Fair Value of Level 3 Derivative Liabilities	The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Schedule of Changes in Fair Value of Level 3 Derivative Liabilities Beginning balance as of January 1, 2021 $ 788,700 Change in fair value of derivative liabilities (228,100 ) Ending balance as of December 31, 2021 $ 560,600 Change in fair value of derivative liabilities 607,001 Reclassify to equity upon conversion of the Notes (1,167,601 ) Ending balance on December 12, 2022 $ -
Schedule of Derivative Liabilities Fair Value Assumption	Schedule of Derivative Liabilities Fair Value Assumption December 31, 2021 Fair value of common stock on date of issuance $ 3.25 Risk free interest rate 0.06 0.19 % Expected term (years) 0.00 0.50 Expected volatility 75 % Expected dividends 0.00 %

Going Concern and Management__2

Going Concern and Management’s Plans (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2022	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 5,902,199	$ 1,278,073
Working capital deficit		5,700,000
Net loss	75,018	3,543,950
Net cash used In operating activities	3,393,888	4,589,452
Accumulated deficit	$ 4,921,178	$ 8,465,128

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

1 Months Ended

3 Months Ended

11 Months Ended

12 Months Ended

Dec. 31, 2022

Dec. 31, 2022

Mar. 31, 2023

Mar. 31, 2022

Dec. 12, 2022

Dec. 31, 2022

Dec. 31, 2021

Reorganization, Chapter 11 [Line Items]

Financial Designation, Predecessor and Successor [Fixed List]

Successor

Successor

Successor

Predecessor

Predecessor

Successor

Predecessor

Total potentially dilutive shares

11,991,694

12,104,694

Warrant [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

[1]

[2]

8,560,561

[1]

2,154,351

[1]

Successor Warrant [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

8,628,695

[1],[3]

8,628,695

[2],[4]

Predecessor Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Successor Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

2,106,235

Series A Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

863,500

[5]

863,500

[6]

Series B Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

506,264

[7]

506,264

[8]

Convertible Notes Payable [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

[9]

[10]

Share-Based Payment Arrangement, Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

1,993,235

Predecessor Series A Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Predecessor [Member]

Reorganization, Chapter 11 [Line Items]

Financial Designation, Predecessor and Successor [Fixed List]

Predecessor

Predecessor

Predecessor

Total potentially dilutive shares

15,828,891

25,006,119

14,309,717

Predecessor [Member] | Warrant [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

2,154,352

[2]

8,560,561

2,154,351

Predecessor [Member] | Successor Warrant [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

[2],[4]

[1],[3]

[1],[3]

Predecessor [Member] | Predecessor Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

9,947,968

10,039,348

8,755,179

Predecessor [Member] | Successor Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Predecessor [Member] | Series A Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Predecessor [Member] | Series B Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Predecessor [Member] | Convertible Notes Payable [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

3,726,571

[10]

[9]

3,400,187

[9]

Predecessor [Member] | Share-Based Payment Arrangement, Option [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

Predecessor [Member] | Predecessor Series A Convertible Preferred Stock [Member]

Reorganization, Chapter 11 [Line Items]

Total potentially dilutive shares

6,406,210

[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor 600,000 119,125 Successor 3,454,000 3,454,000 3,454,000 2.00 216,970 216,970 7.00 3.25 3.00

Schedule of Anti-dilutive Exclu

Schedule of Anti-dilutive Excluded from Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - $ / shares		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Fair value of common stock				$ 3			$ 3.25
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares available for conversion		3,454,000	3,454,000
Conversion floor price			$ 2
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares available for conversion		216,970	216,970
Conversion floor price			$ 7
Series A Warrant Exercise [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares available for conversion		3,454,000	4,101,625
Conversion floor price			$ 2
Inflamacore LlC License Agreement [Member] | Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants to purchase common shares	119,125	119,125	119,125	600,000	600,000	119,125

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Mar. 31, 2023		Dec. 31, 2022		Dec. 31, 2021
Payables and Accruals [Abstract]
L&F milestone payment liability		$ 500,000		$ 1,500,000		$ 1,500,000
L&F Note			[1]	(351,579)	[1]	(351,579)
L&F, net		500,000		1,148,421		1,148,421
Payroll accrual		291,552		584,226
Other accrued expenses		51,968		214,229
Federal income tax payable		106,683		106,683
Bonus accrual		764,590
Registration delay liability	[2]	398,019
Accrued interest						748,767
Deferred rent						16,913
Total accrued expenses and other current liabilities		$ 2,112,812		$ 2,053,559		$ 1,914,101
[1]See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note.[2]See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative)	1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 12, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)
Reorganization, Chapter 11 [Line Items]
Derivative liabilities	$ 0	$ 0
Change in fair value of derivative liabilities				$ (607,001)	$ (228,100)
Conversion of convertible notes payable | shares				2,940,537
Conversion price | $ / shares				$ 1.58835
Change in fair value of derivative liabilities				$ 186,401
Percentage of qualified offering occurring					85%
Percentage of change of control occuring					0%
Measurement Input, Discount Rate [Member]
Reorganization, Chapter 11 [Line Items]
Discount rate					25
Common Stock Payable [Member]
Reorganization, Chapter 11 [Line Items]
Fair value price percentage				80%
Fair value per share | $ / shares				$ 1.98542
Fair value consideration redemption				5,838,209
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Change in fair value of derivative liabilities			$ 212,100	$ 607,001	$ (228,100)

Schedule of Income Tax Expense

Schedule of Income Tax Expense and the Effective Tax Rate (Details) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Income tax benefit		$ 745,050	$ 1,047,051
Effective tax rate		90.80%	22.81%
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Income tax benefit
Effective tax rate				0%	(0.00%)		0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Effective tax rate		90.80%	22.81%
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Net operating loss carry forwards, federal	$ 27,515,427	$ 27,515,427				$ 27,515,427
Net operating loss carry forwards, state	20,567,703	20,567,703				20,567,703
Valuation allowance
Change in valuation allowance		$ 558,581
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Effective tax rate				0%	(0.00%)		0%
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Net operating loss carry forwards, federal					$ 27,385,445		$ 20,446,200
Net operating loss carry forwards, state					20,458,902		14,644,000
Valuation allowance					2,673,627		2,244,084
Valuation allowance					14,853,648		12,180,021
Change in valuation allowance					$ (2,673,627)		$ (2,244,084)

Schedule of Right of Use Assets

Schedule of Right of Use Assets and Liabilities (Details) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Operating cash flows used in operating activities			$ 24,248			$ 4,786
Operating leases
Weighted average remaining lease term	1 year 29 days	1 year 29 days	10 months 2 days		1 year 29 days	1 year 29 days
Weighted average discount rate	6.50%	6.50%	6.50%		6.50%	6.50%
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Operating cash flows used in operating activities				$ 22,028	$ 86,100
Operating leases
Weighted average remaining lease term				1 year 10 months 2 days
Weighted average discount rate				6.50%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Lease (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Future minimum payments	$ 87,054	$ 112,916
Less: amount representing imputed interest	(2,547)	(4,160)
Total	$ 84,507	$ 108,756

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)														1 Months Ended		3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 29, 2023 USD ($) shares	Feb. 28, 2023 USD ($)	Feb. 20, 2023 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 23, 2022 USD ($)	Aug. 26, 2022 USD ($)	Mar. 07, 2022 USD ($)	Dec. 15, 2021 USD ($)	Dec. 15, 2020 USD ($) shares	Jan. 09, 2020 USD ($)	Apr. 18, 2019 USD ($) $ / shares shares	Jan. 18, 2019 USD ($) ft²	Dec. 15, 2015 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Dec. 12, 2022 USD ($) shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Mar. 10, 2023 shares	May 10, 2022 $ / shares
Loss Contingencies [Line Items]
Milestone payment description		On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).
Cash payment			$ 398,000
Reclassification shares of common stock | shares				65,783										65,783	65,783	0			65,783	65,783
Reclassification shares of common stock value classified as temporary to permanent equity				$ 331,331										$ 331,331	$ 331,331				$ 331,331	$ 331,331
Financial Designation, Predecessor and Successor [Fixed List]				Successor										Successor		Successor	Predecessor	Predecessor	Successor		Predecessor
Operating lease asset amortization																$ 38,415
License agreements up front cash payment													$ 200,000
Aggregate milestone cash payments								$ 500,000	$ 1,500,000	$ 1,000,000	$ 22,500,000		21,500,000
Second license agreement milestone													2,500,000
Aggregate common stock shares | shares				9,016,139										9,016,139	9,016,139	9,211,922			9,016,139	9,016,139
Aggregate common stock exercise price share | $ / shares				$ 11.50										$ 11.50	$ 11.50				$ 11.50	$ 11.50
Fair value of grant date excerisable													$ 766,384
License agreements payable upon commencement of Phase 2a										500,000
License agreements payable										500,000
Cash payment exercise price withheld										$ 351,579
Aggregate milestone cash payments, description											the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%.
Aggregate common stock shares | shares																						5,000
Operating lease rent expense																				$ 7,795
Warrant [Member]
Loss Contingencies [Line Items]
Aggregate common stock exercise price share | $ / shares				$ 11.50										$ 11.50	$ 11.50				$ 11.50	$ 11.50
Minimum [Member]
Loss Contingencies [Line Items]
Percentage of product sales													5%
Maximum [Member]
Loss Contingencies [Line Items]
Percentage of product sales													10%
Predecessor [Member]
Loss Contingencies [Line Items]
Reclassification shares of common stock | shares																					331,331
Reclassification shares of common stock value classified as temporary to permanent equity																					$ 331,331
Number of operating lease square feet | ft²												3,500
Sublease base rent												$ 89,000
Lease base rent lease commitment												497,000
Financial Designation, Predecessor and Successor [Fixed List]																	Predecessor	Predecessor			Predecessor
Operating lease rent expense																	$ 38,141
License agreements up front cash payment											$ 346,321
Aggregate common stock shares | shares																					24,167,257
Fair value of grant date excerisable											$ 815,822
Fair value of excerisable period													period of five years
Aggregate common stock shares | shares											400,000
Sublease base rent lease commitment												$ 497,000
Operating lease rent expense																		$ 148,881			$ 148,125
Predecessor [Member] | Research and Development Expense [Member]
Loss Contingencies [Line Items]
Fair value of grant date excerisable											$ 460,000		$ 306,411
Common stock fair value											$ 200,000
Predecessor [Member] | Warrant [Member]
Loss Contingencies [Line Items]
Aggregate common stock shares | shares											600,000		878,947
Aggregate common stock exercise price share | $ / shares											$ 2.30		$ 1										$ 3.20
Fair value of grant date excerisable															$ 153,324
Aggregate common stock shares | shares				351,578					175,789				351,579	351,578	351,578			6,406,210	351,578	351,578
Aggregate common stock shares | shares											1,000,000
License Agreement [Member] | L&F Research LLC [Member]
Loss Contingencies [Line Items]
Milestone payments					$ 1,500,000	$ 1,500,000	$ 1,500,000
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]
Loss Contingencies [Line Items]
Net proceeds from issuance of equity capital		$ 30,000,000
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]
Loss Contingencies [Line Items]
Reclassification shares of common stock | shares	65,783
Reclassification shares of common stock value classified as temporary to permanent equity	$ 331,331
Waiver A [Member]
Loss Contingencies [Line Items]
Debt forgiveness	351,579	351,579
Cash payment	$ 648,421	$ 648,421
Maturity date		Mar. 31, 2023
Waiver B [Member]
Loss Contingencies [Line Items]
Cash payment		$ 500,000
Maturity date		Jan. 31, 2024

Schedule of Stock Options Grant

Schedule of Stock Options Granted (Details) - $ / shares		1 Months Ended	3 Months Ended		11 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 12, 2021	Dec. 31, 2022	Dec. 31, 2021
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor		Successor	Predecessor
Expected term (years)			6 years
Expected dividends			0%
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor			Predecessor
Fair value of common stock on date of grant				$ 3				$ 3.25
Expected dividends				0%	0%			0%
Minimum [Member]
Fair value of common stock on date of grant			$ 2.11
Risk free interest rate			3.53%
Expected volatility			120%
Minimum [Member] | Predecessor [Member]
Fair value of common stock on date of grant					$ 2.27
Risk free interest rate				1.68%	1.68%			0.66%
Expected term (years)				3 years 6 months 10 days	3 years 6 months 10 days			5 years
Expected volatility				111%	111%			118%
Maximum [Member]
Fair value of common stock on date of grant			$ 2.23
Risk free interest rate			4.27%
Expected volatility			122%
Maximum [Member] | Predecessor [Member]
Fair value of common stock on date of grant					$ 3
Risk free interest rate				2.42%	3.01%	1.26%
Expected term (years)				6 years	6 years	6 years
Expected volatility				119%	119%			125%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)				1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 10, 2023	Jan. 27, 2023	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Number of options, outstanding beginning balance				1,993,235	1,993,235
Weighted average exercise price, outstanding, beginning balance				$ 10.81	$ 10.81
Number of options, granted					113,000
Weighted average exercise price, granted					$ 2.13
Number of options, exercised
Weighted average exercise price, exercised
Number of options, forfeited
Weighted average exercise price, forfeited
Number of options, outstanding ending balance			1,993,235	1,993,235	2,106,235		1,993,235	1,993,235
Weighted average exercise price, outstanding, ending balance			$ 10.81	$ 10.81	$ 10.35		$ 10.81	$ 10.81
Weighted average remaining life in years, outstanding				5 years 9 months 18 days	5 years 7 months 6 days
Aggregate intrinsic value, ending balance	$ 23,770	$ 184,426
Number of options, exercisable ending balance			1,639,566	1,639,566	1,783,531			1,639,566
Weighted average exercise price, Exercisable			$ 9.63	$ 9.63	$ 10.18			$ 9.63
Weighted average remaining life in years, exercisable				5 years 3 months 18 days	5 years 3 months 18 days
Aggregate intrinsic value, exercisable
Financial Designation, Predecessor and Successor [Fixed List]			Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Number of options, outstanding beginning balance						10,039,348	10,039,348	10,039,348	8,755,179
Weighted average exercise price, outstanding, beginning balance						$ 2.15	$ 2.15	$ 2.15	$ 2
Number of options, granted									1,284,169
Weighted average exercise price, granted									$ 3.17
Number of options, exercised
Weighted average exercise price, exercised
Number of options, forfeited
Weighted average exercise price, forfeited
Number of options, outstanding ending balance									10,039,348
Weighted average exercise price, outstanding, ending balance									$ 2.15
Weighted average remaining life in years, outstanding									5 years 10 months 24 days
Aggregate intrinsic value, ending balance									$ 3,271,992
Number of options, exercisable ending balance									8,258,023
Weighted average exercise price, Exercisable									$ 1.91
Weighted average remaining life in years, exercisable									5 years 3 months 18 days
Aggregate intrinsic value, exercisable									$ 3,271,992
Financial Designation, Predecessor and Successor [Fixed List]						Predecessor	Predecessor		Predecessor

Schedule of Information Related

Schedule of Information Related to Stock Options (Details) - $ / shares		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 10, 2023	Jan. 27, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price								$ 2.26	$ 2.11
Options outstanding, Number of options	1,993,235	1,993,235	2,106,235			1,993,235		13,000	100,000
Options exercisable, Number of options	1,639,566	1,639,566	1,783,531			1,639,566
Options exercisable, weighted average remaining life in life			5 years 3 months 18 days			5 years 3 months 18 days
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 5.03	$ 5.03	$ 2.11			$ 5.03
Options outstanding, Number of options	662,887	662,887	100,000			662,887
Options exercisable, Number of options	662,887	662,887				662,887
Options exercisable, weighted average remaining life in life						3 years 1 month 6 days
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 11.33	$ 11.33	$ 2.26			$ 11.33
Options outstanding, Number of options	12,186	12,186	13,000			12,186
Options exercisable, Number of options	12,186	12,186				12,186
Options exercisable, weighted average remaining life in life						9 years 6 months
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 11.58	$ 11.58	$ 5.03			$ 11.58
Options outstanding, Number of options	728,430	728,430	662,887			728,430
Options exercisable, Number of options	723,576	723,576	662,887			723,576
Options exercisable, weighted average remaining life in life			2 years 9 months 18 days			6 years 3 months 18 days
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 16.36	$ 16.36	$ 11.33			$ 16.36
Options outstanding, Number of options	589,732	589,732	12,186			589,732
Options exercisable, Number of options	240,917	240,917	12,186			240,917
Options exercisable, weighted average remaining life in life			9 years 3 months 18 days			8 years 3 months 18 days
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price			$ 11.58
Options outstanding, Number of options			728,430
Options exercisable, Number of options			723,576
Options exercisable, weighted average remaining life in life			6 years
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price			$ 16.36
Options outstanding, Number of options			589,732
Options exercisable, Number of options			384,882
Options exercisable, weighted average remaining life in life			8 years 1 month 6 days

Stockholders_ Permanent and T_3

Stockholders’ Permanent and Temporary Equity (Details Narrative)															1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Mar. 10, 2023 USD ($) $ / shares shares	Feb. 20, 2023 USD ($)	Jan. 27, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 12, 2022 $ / shares shares	Dec. 12, 2022 $ / shares shares	Dec. 06, 2022 USD ($) $ / shares shares	Sep. 22, 2022 $ / shares	Sep. 16, 2022 USD ($) $ / shares shares	Aug. 31, 2022 USD ($) $ / shares	Jul. 08, 2022 USD ($) $ / shares shares	May 10, 2022 $ / shares	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 13, 2020 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares	Dec. 12, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 13, 2022 $ / shares	Dec. 31, 2020 shares	Dec. 15, 2020 shares	Apr. 18, 2019 $ / shares shares	Dec. 15, 2015 $ / shares shares
Class of Stock [Line Items]
Shares issued	5,000
Issuance of common stock value | $																$ 395,200
Financial Designation, Predecessor and Successor [Fixed List]				Successor											Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Stock based compensation expense | $															$ 56,333	$ 287,461		$ 3,524,802		$ 4,245,463
Unrecognized stock-based compensation expense | $				$ 2,957,047											$ 2,957,047	$ 1,595,639			$ 2,957,047
weighted average period						1 year 7 months 6 days										1 year 7 months 6 days
Weighted average remaining life, granted options	ten-year		ten-year
Number of options outstanding	13,000		100,000	1,993,235											1,993,235	2,106,235			1,993,235
Aggregate grant date value | $	$ 23,770		$ 184,426
Weighted average remaining life, vested options			3 years
Options outstanding, exercise price | $ / shares	$ 2.26		$ 2.11
Weighted average remaining life, vested options	3 years
Percentage of registration delay payments		1.50%
Interest rate		2%
Registration delay cash payment | $		$ 398,000
Common stock, shares authorized				110,000,000											110,000,000	110,000,000			110,000,000
Common stock, par value | $ / shares				$ 0.0001											$ 0.0001	$ 0.0001			$ 0.0001
Preferred stock, shares authorized				1,000,000											1,000,000	1,000,000			1,000,000	1,000,000
Preferred stock, par value | $ / shares				$ 0.0001											$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Share price, per share | $ / shares																					$ 5.04
Additional paid in capital | $				$ 104,583,271											$ 104,583,271	$ 105,562,569			$ 104,583,271
Common stock exchanged during acquisition					331,331
Warrant exercise price share | $ / shares				$ 11.50											$ 11.50				$ 11.50
Number of options outstanding				1,993,235	1,993,235	1,993,235									1,993,235	2,106,235		1,993,235	1,993,235
Shares issued, price per share | $ / shares													$ 3				$ 3			$ 3.25
Satisfaction of company liabilities | $				$ 5,062,000											$ 5,062,000				$ 5,062,000
Share exchange ration															5.037				5.037
Company valuation | $																			$ 85,000,000
Replacement warrants exercisable															The Replacement Warrants include (a) exercisable warrants to purchase 1,271,904 shares of Successor common stock with an exercise price of $6.90 per share and with an expiration date of December 12, 2027, which replace the warrants that were issued by the Predecessor to its Series A Preferred Stock holders upon the automatic conversion of their Predecessor Series A Preferred Stock into Predecessor common stock and Predecessor Series A Warrants upon the closing of the Business Combination (see Note 11 – Stockholders’ Permanent and Temporary Equity – Automatic Conversion of Predecessor Series A Preferred Stock); (b) warrants to purchase 104,704 shares of Successor common stock with an exercise price of $5.03 per share which replace the warrants that were issued by the Predecessor to a strategic partner (see Note 10 – Commitments and Contingencies – License Agreements – L&F Research LLC), of which warrants to purchase 34,901 shares are exercisable until they expire on or about January 6, 2025, while the remainder vest upon the achievement of certain milestones and expire five years following the achievement of those milestones; and (c) exercisable warrants to purchase 323,026 shares of Successor common stock with an exercise price of $11.58 per share and with various expiration dates through April 17, 2024 which replace the warrants that were issued by the Predecessor to certain purchasers of convertible notes, certain brokers and a strategic partner in conjunction with entering into a license agreement (see Note 10 – Commitments and Contingencies – License Agreements – InflamaCORE).
Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Number of options outstanding				1,993,235											1,993,235				1,993,235
Share exchange ration																			5.037
Options Held [Member]
Class of Stock [Line Items]
Number of options outstanding				1,993,235											1,993,235				1,993,235
Warrant [Member]
Class of Stock [Line Items]
Exercisable warrants				863,500											863,500				863,500
Replacement Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase shares				1,699,633											1,699,633				1,699,633
Warrant [Member]
Class of Stock [Line Items]
Share price, per share | $ / shares				$ 0.01											$ 0.01				$ 0.01
Warrant exercise price share | $ / shares				11.50											11.50				11.50
Shares issued, price per share | $ / shares				1,000											1,000				$ 1,000
Share exchange ration																			5.037
Closing price of common stock | $ / shares															18
Larkspur Larkspur Merger Sub Inc [Member]
Class of Stock [Line Items]
Common stock exchanged during acquisition					65,783
Larkspur Larkspur Merger Sub Inc [Member] | Warrant [Member]
Class of Stock [Line Items]
Warrant exercise price share | $ / shares				$ 11.50											$ 11.50				$ 11.50
Shares of common stock				6,065,573											6,065,573				6,065,573
Put Option [Member]
Class of Stock [Line Items]
Additional paid in capital | $														$ 331
P I P E Warrant [Member]
Class of Stock [Line Items]
Preferred stock sold																863,500
Preferred stock price per share | $ / shares																$ 1,000
Net proceeds | $																$ 8,635,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock sold																8,635
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Net proceeds | $															$ 8,635,000
Preferred stock, shares authorized				8,635											8,635	8,635			8,635
Preferred stock, shares designated				8,635											8,635	8,635			8,635
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock sold															8,635
Preferred stock, shares authorized				5,062											5,062	5,062			5,062	5,062
Warrants to purchase shares				863,500											863,500				863,500
Shares issued, price per share | $ / shares				$ 1,000											$ 1,000				$ 1,000
Preferred stock, shares designated				5,062											5,062	5,062			5,062	5,062
Shares conversion price | $ / shares				$ 10											$ 10				$ 10
Series B Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Shares conversion price | $ / shares				$ 7											$ 7				$ 7
Predecessor [Member]
Class of Stock [Line Items]
Issuance of common stock value | $
Financial Designation, Predecessor and Successor [Fixed List]																	Predecessor	Predecessor		Predecessor
Stock based compensation expense | $																	$ 1,941,746
Aggregate grant date value | $																				$ 3,271,992
Common stock, shares authorized					75,000,000	75,000,000												75,000,000		75,000,000
Common stock, par value | $ / shares					$ 0.00001	$ 0.00001												$ 0.00001		$ 0.00001
Preferred stock, shares authorized					5,000,000	5,000,000												5,000,000
Preferred stock, par value | $ / shares					$ 0.00001	$ 0.00001												$ 0.00001
Additional paid in capital | $																				$ 40,065,109
Proceeds from related party debt | $																		$ 0		$ 3,150,000
Placement agent fees | $							$ 2,000		$ 16,000		$ 21,200
Incremental fair value of stock and warrants | $																			$ 331,200
Aggregate common stock of warrant exercise price share | $ / shares										$ 3.20
Warrant, Exercise Price, Decrease | $ / shares								$ 1.37
Number of options outstanding																				10,039,348		8,755,179
Share exchange					6,406,210
Warrants to purchase shares																								400,000
Share exchange ration																		5.037
Company valuation | $																		$ 85,000,000
Predecessor [Member] | Share-Based Payment Arrangement, Option [Member]
Class of Stock [Line Items]
Number of options outstanding					10,039,348	10,039,348												10,039,348
Share exchange ration																		5.037
Predecessor [Member] | Warrant [Member]
Class of Stock [Line Items]
Shares issued																								1,000,000
Warrant exercise price share | $ / shares												$ 3.20												$ 2.30	$ 1
Aggregate common stock of warrant exercise price share | $ / shares					$ 6.90
Warrants to purchase shares				351,578	6,406,210	6,406,210									351,578			6,406,210	351,578				175,789		351,579
Warrant exchange					1,271,904
Predecessor [Member] | Second Amendment Securities [Member]
Class of Stock [Line Items]
Incremental fair value of stock and warrants | $										$ 9,684,637
Predecessor [Member] | Predecessor Common Stock [Member]
Class of Stock [Line Items]
Number of options outstanding					8,560,561	8,560,561												8,560,561
Predecessor [Member] | Larkspur Larkspur Merger Sub Inc [Member]
Class of Stock [Line Items]
Share exchange																			33,845,335
Predecessor [Member] | Put Option [Member]
Class of Stock [Line Items]
Put option purchase of common stock														331,331
Share price, per share | $ / shares														$ 1
Predecessor [Member] | Series A Preferred Stock [Member]
Class of Stock [Line Items]
Net proceeds | $													$ 392,301
Proceeds from related party debt | $													$ 100,000
Gross proceeds | $							$ 548,805		$ 700,000		$ 296,400
Preferred stock conversion price per share | $ / shares										$ 2.78		3.14
Preferred stock conversion price per share | $ / shares										$ 1.19		$ 2.78
Number of options outstanding					2,427,832	2,427,832												2,427,832
Predecessor [Member] | Series A Preferred Stock [Member] | Investor [Member]
Class of Stock [Line Items]
Preferred stock sold							174,776		222,929		94,393		133,541
Preferred stock price per share | $ / shares							$ 3.14		$ 3.14		$ 3.14		$ 3.14				$ 3.14
Research and Development Expense [Member]
Class of Stock [Line Items]
Stock based compensation expense | $															$ 7,808	$ 49,455		$ 673,160		$ 944,525
Research and Development Expense [Member] | Predecessor [Member]
Class of Stock [Line Items]
Stock based compensation expense | $																	$ 307,838
General and Administrative Expense [Member]
Class of Stock [Line Items]
Stock based compensation expense | $															$ 48,525	$ 238,006		$ 2,851,642		$ 3,300,938
General and Administrative Expense [Member] | Predecessor [Member]
Class of Stock [Line Items]
Stock based compensation expense | $																	$ 1,633,908
Marketing Agreements [Member]
Class of Stock [Line Items]
Shares issued																130,000
Issuance of common stock value | $																$ 395,200
2014 Equity Incentive Plan [Member] | Predecessor [Member]
Class of Stock [Line Items]
Common stock, shares authorized																				10,000,000
Equity incentive plan, description																				The number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on the first trading day of January each calendar year during the term of the 2014 Plan, beginning with calendar year 2019, by an amount equal to five percent (5%) of the total number of shares of common stock outstanding on the last trading day in December of the immediately preceding calendar year, but in no event shall any such annual increase exceed 100,000 shares of common stock.
Common stock future issuance					45,652	45,652												45,652
2022 Omnibus Equity Incentive Plan [Member]
Class of Stock [Line Items]
Common stock, shares authorized				1,089,831											1,089,831				1,089,831
Common stock future issuance				1,089,831											1,089,831				1,089,831

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

11 Months Ended

12 Months Ended

Jun. 05, 2023

May 24, 2023

May 19, 2023

Apr. 28, 2023

Mar. 29, 2023

Mar. 10, 2023

Feb. 28, 2023

Feb. 20, 2023

Jan. 27, 2023

Dec. 31, 2022

Dec. 31, 2022

Mar. 31, 2023

Mar. 31, 2022

Dec. 12, 2022

Dec. 31, 2022

Dec. 31, 2021

Subsequent Event [Line Items]

Floor price

$ 11.50

$ 11.50

$ 11.50

Issuance costs

$ 395,200

Exercisable common stock, shares

1,639,566

1,639,566

1,783,531

1,639,566

Weighted average remaining life, granted options

ten-year

ten-year

Number of options outstanding

13,000

100,000

1,993,235

1,993,235

2,106,235

1,993,235

Options outstanding, exercise price

$ 2.26

$ 2.11

Weighted average remaining life, vested options

3 years

Milestone payment description

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).

Cash payment

$ 398,000

Stock option to purchase

Financial Designation, Predecessor and Successor [Fixed List]

Successor

Successor

Successor

Predecessor

Predecessor

Successor

Predecessor

Interest rate

2%

Cash FDIC insured amount

$ 250,000

$ 250,000

$ 250,000

Estimated useful life

5 years

5 years

5 years

Equipment

$ 52,000

$ 52,000

$ 52,000

$ 52,000

Accumulated depreciation

34,667

$ 24,267

Depreciation

532

$ 2,600

$ 9,869

Company valuation

85,000,000

Operating lease right of use asset

98,371

98,371

$ 76,324

98,371

Accounting Standards Update 2016-02 [Member]

Subsequent Event [Line Items]

Operating lease right of use asset

182,732

182,732

182,732

Operating lease liability

199,642

199,642

199,642

Deferred rent

$ 16,910

$ 16,910

$ 16,910

Waiver A [Member]

Subsequent Event [Line Items]

Debt forgiveness

$ 351,579

$ 351,579

Cash payment

648,421

$ 648,421

Maturity date

Mar. 31, 2023

Waiver B [Member]

Subsequent Event [Line Items]

Cash payment

$ 500,000

Maturity date

Jan. 31, 2024

Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Warrants to purchase common shares

863,500

863,500

863,500

Common Stock [Member]

Subsequent Event [Line Items]

Common stock, sponsor

130,000

Issuance costs

$ 13

Subsequent Event [Member]

Subsequent Event [Line Items]

Payment to redemption of original PIPE shares amount

$ 10,100,000

Percentage of premium redemption of original PIPE

20%

Premium amount of PIPE Shares

$ 1,700,000

Payment of Effectiveness Failure amount

400,000

Remaining PIPE Shares amount

$ 200,000

Common stock floor conversion price per share

$ 2

Weighted average remaining life, granted options

ten-year

Number of options outstanding

1,453,107

Options outstanding, exercise price

$ 0.44

Shares vested

150,000

Weighted average remaining life, vested options

3 years

Milestone payment description

On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the license agreement or any other remedies, for non-payment of the $1,500,000 of milestone payments, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (‘Waiver B”).

Cash payment

$ 260,000

Minimum waiver amount

$ 30,000,000

Stock option to purchase

13,000

100,000

Stock option exercise price per share

$ 2.26

$ 2.11

Interest rate

2%

Subsequent Event [Member] | Waiver A [Member]

Subsequent Event [Line Items]

Debt forgiveness

351,579

Cash payment

$ 648,421

$ 648,421

Maturity date

Mar. 31, 2023

Subsequent Event [Member] | Waiver B [Member]

Subsequent Event [Line Items]

Cash payment

$ 500,000

Maturity date

Jan. 31, 2024

Subsequent Event [Member] | Executive Officer [Member]

Subsequent Event [Line Items]

Stock option to purchase

5,000

Subsequent Event [Member] | Series B Preferred Stock [Member]

Subsequent Event [Line Items]

Common stock, sponsor

5,062

Floor price

$ 7

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Common stock, sponsor

11,015,500

Warrants to purchase common shares

11,015,500

Gross proceeds

$ 11,000,000

Floor price

$ 1

Issuance costs

$ 500,000

Placement fees

$ 400,000

Subsequent Event [Member] | Common Stock [Member] | Consultant [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Issued for Services

380,000

Subsequent Event [Member] | Common Stock [Member] | Pipe Financing [Member]

Subsequent Event [Line Items]

Warrants to purchase common shares

863,500

Floor price

$ 2

Exercisable common stock, shares

4,965,125

Subsequent Event [Member] | Common Stock [Member] | Private Placement [Member] | Sponsor [Member]

Subsequent Event [Line Items]

Common stock, sponsor

3,044,152

Schedule of Fair Value of the P

Schedule of Fair Value of the Purchase Consideration (Details) - Larkspur Larkspur Merger Sub Inc [Member]	1 Months Ended
	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Total fair value of the purchase consideration	$ 91,251,871
Common Stock [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	67,197,300
Warrant [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	12,190,015
Share-Based Payment Arrangement, Option [Member]
Business Acquisition [Line Items]
Total fair value of the purchase consideration	$ 11,864,556

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Current assets, including cash of $699,324		$ 1,093,223
In-process research and development		100,086,329
Goodwill	$ 11,895,033	11,895,033
Other non-current assets		64,523
Total assets acquired		113,139,108
Current liabilities		10,818,204
Deferred tax liabilities		11,069,033
Total assumed liabilities		21,887,237
Net assets acquired		$ 91,251,871

Schedule of Estimated Fair Va_2

Schedule of Estimated Fair Values of Identifiable Net Assets Acquired Recorded as Goodwill (Details) (Parentheticals)	Dec. 31, 2022 USD ($)
Business Combination and Asset Acquisition [Abstract]
Cash	$ 699,324

Business Combination (Details N

Business Combination (Details Narrative)				1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022 shares	Dec. 12, 2022 shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Mar. 31, 2023 shares	Mar. 31, 2022	Dec. 12, 2022 USD ($) shares	Dec. 31, 2022 shares	Dec. 31, 2021 shares	Dec. 31, 2020 shares
Business Acquisition [Line Items]
Share issued on conversion								6,719,730
Financial Designation, Predecessor and Successor [Fixed List]	Successor			Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Share exchange ration				5.037				5.037
Number of options outstanding	1,993,235	1,993,235		1,993,235	2,106,235		1,993,235	1,993,235
Series A Preferred Stock [Member]
Business Acquisition [Line Items]
Net proceeds | $				$ 8,635,000
Share-Based Payment Arrangement, Option [Member]
Business Acquisition [Line Items]
Share exchange ration								5.037
Number of options outstanding	1,993,235			1,993,235				1,993,235
Replacement of Options	1,731,237			1,731,237				1,731,237
Warrant [Member]
Business Acquisition [Line Items]
Replacement of warrants	584,260			584,260				584,260
Warrant [Member]
Business Acquisition [Line Items]
Share exchange ration								5.037
Replacement of warrants	1,699,633			1,699,633				1,699,633
Predecessor [Member]
Business Acquisition [Line Items]
Share exchange		6,406,210
Financial Designation, Predecessor and Successor [Fixed List]						Predecessor	Predecessor		Predecessor
Share exchange ration							5.037
Number of options outstanding									10,039,348	8,755,179
Transaction costs | $							$ 2,100,000
Predecessor [Member] | Series A Preferred Stock [Member]
Business Acquisition [Line Items]
Number of options outstanding		2,427,832					2,427,832
Net proceeds | $			$ 392,301
Predecessor [Member] | Share-Based Payment Arrangement, Option [Member]
Business Acquisition [Line Items]
Share exchange ration							5.037
Number of options outstanding		10,039,348					10,039,348
Predecessor [Member] | Warrant [Member]
Business Acquisition [Line Items]
Replacement of warrants		8,560,561					8,560,561
Larkspur Larkspur Merger Sub Inc [Member] | Permanent Equity Shares [Member]
Business Acquisition [Line Items]
Share exchange								33,514,004
Larkspur Larkspur Merger Sub Inc [Member] | Temporary Shares [Member]
Business Acquisition [Line Items]
Share exchange								331,331
Larkspur Larkspur Merger Sub Inc [Member] | Predecessor [Member]
Business Acquisition [Line Items]
Share exchange								33,845,335

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	Dec. 13, 2020	Feb. 20, 2023	Dec. 12, 2022
Short-Term Debt [Line Items]
Debt instrument face amount			$ 3,961,000
Debt instrument interest rate		2%
L&F Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount	$ 351,579
Debt instrument interest rate	1.17%
Prepay of note, description	L&F is required to immediately prepay the L&F Note and all accrued and unpaid interest on the L&F Note with the following: (a) 100% of the proceeds of the second $500,000 of milestone payments paid by ZyVersa to L&F pursuant to the terms of the license agreement (See Note 10- Commitments and Contingencies), (b) 100% of the gross proceeds from the sale of common stock by L&F to ZyVersa pursuant to the terms of the Put Option (See Note 11 – Stockholders’ Permanent and Temporary Equity), (c) 100% of the gross proceeds in excess of $1.00 per share from the sale of ZyVersa common stock by L&F to any party other than ZyVersa and (d) proceeds received in connection with certain liquidation events as defined in the agreement. Commencing on December 13, 2021 and, so long as the principal amount of the L&F Note remains outstanding, on each December 13 through December 13, 2025, the Company will pay L&F an annual administrative fee equal to $6,000.
Debt instrument milestone payment	$ 500,000
Administrative fee	$ 6,000

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Level 3 Derivative Liabilities (Details) - USD ($)	1 Months Ended	3 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Dec. 12, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Derivative Liability, Current			$ 560,600	$ 788,700
Change in fair value of derivative liabilities			(607,001)	(228,100)
Change in fair value of derivative liabilities			607,001	228,100
Reclassify to equity upon converstion of the Notes			(1,167,601)
Derivative Liability, Current				$ 560,600

Schedule of Derivative Liabilit

Schedule of Derivative Liabilities Fair Value Assumption (Details)	12 Months Ended
	Dec. 31, 2021
Minimum [Member]
Debt Instrument [Line Items]
Expected term (years)	0 years
Maximum [Member]
Debt Instrument [Line Items]
Expected term (years)	6 months
Measurement Input, Share Price [Member]
Debt Instrument [Line Items]
Derivative liability measurement input	3.25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability measurement input	0.06
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability measurement input	0.19
Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Derivative liability measurement input	75
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability measurement input	0

Schedule of Provision For Incom

Schedule of Provision For Income Taxes (Details) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Deferred tax benefit:
Federal		$ (151,625)
State		(34,844)
Deferred tax benefit		(186,469)
Change in valuation allowance		(558,581)
Provision for income taxes		$ (745,050)	$ (1,047,051)
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Deferred tax benefit:
Federal					$ (2,191,344)		$ (1,480,472)
State					(482,283)		(763,612)
Deferred tax benefit					(2,673,627)		(2,244,084)
Change in valuation allowance					2,673,627		2,244,084
Provision for income taxes

Schedule of Provision For Inc_2

Schedule of Provision For Income Taxes Differs From The Federal Statutory Rate (Details)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Federal statutory rate		21%
State tax rate, net of federal benefit		3.60%
Permanent items		(1.90%)
Nondeductible basis difference		0%
Effect of change in state rate		0%
Prior period adjustments and other		0%
Change in valuation allowance		68.10%
Effective income tax rate		90.80%	22.81%
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Federal statutory rate					21%		21%
State tax rate, net of federal benefit					3.60%		3.70%
Permanent items					(5.40%)		(0.90%)
Nondeductible basis difference					0%		0.10%
Effect of change in state rate					(0.10%)		3.90%
Prior period adjustments and other					(0.10%)		0%
Change in valuation allowance					(19.00%)		(27.80%)
Effective income tax rate				0%	(0.00%)		0%

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Net operating loss carryforwards	$ 6,671,907	$ 6,671,907				$ 6,671,907
Stock-based compensation expense	2,936,945	2,936,945				2,936,945
Capitalized research and development costs	2,421,390	2,421,390				2,421,390
Capitalized start-up costs	1,121,802	1,121,802				1,121,802
Capitalized licensing costs	687,926	687,926				687,926
Derivative liabilities
Capitalized patents	288,123	288,123				288,123
Warrants	133,203	133,203				133,203
Accrued payroll	71,830	71,830				71,830
Contributions carryforward	2,833	2,833				2,833
Lease liabilities	26,794	26,794				26,794
Deferred rent
Deferred tax assets	14,362,753	14,362,753				14,362,753
Valuation allowance
Deferred tax assets	14,362,753	14,362,753				14,362,753
Deferred debt discount
Right-of-use asset	(24,236)	(24,236)				(24,236)
In-process research and development	(24,658,231)	(24,658,231)				(24,658,231)
Fixed assets	(4,270)	(4,270)				(4,270)
Deferred tax liabilities	(24,686,737)	(24,686,737)				(24,686,737)
Deferred tax assets, net	$ (10,323,984)	$ (10,323,984)				$ (10,323,984)
Predecessor [Member]
Reorganization, Chapter 11 [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Net operating loss carryforwards					$ 6,639,882		$ 4,930,055
Stock-based compensation expense					4,084,595		3,220,799
Capitalized research and development costs					2,362,939		2,199,126
Capitalized start-up costs					565,530		620,016
Capitalized licensing costs					689,820		735,485
Derivative liabilities							6,388
Capitalized patents					273,682		235,065
Warrants					238,768		239,307
Accrued payroll
Contributions carryforward					2,833		2,840
Lease liabilities
Deferred rent							4,176
Deferred tax assets					14,858,049		12,193,257
Valuation allowance					(14,853,648)		(12,180,021)
Deferred tax assets					4,401		13,236
Deferred debt discount							(6,388)
Right-of-use asset
In-process research and development
Fixed assets					(4,401)		(6,848)
Deferred tax liabilities					(4,401)		(13,236)
Deferred tax assets, net

Summary of Warrant Activity (De

Summary of Warrant Activity (Details) - USD ($)		1 Months Ended	3 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor	Predecessor	Predecessor	Successor	Predecessor
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]				Predecessor	Predecessor		Predecessor
Warrant [Member]
Number of warrants, outstanding, beginning balance		8,628,706	8,628,706
Weighted average exercise price, outstanding, beginning balance		$ 10.75	$ 10.75
Number of warrants, Issued
Weighted average exercise price, issued
Number of warrants, outstanding, ending balance	8,628,706	8,628,706			8,628,706	8,628,706
Weighted average exercise price, outstanding, ending balance	$ 10.75	$ 10.75			$ 10.75	$ 10.75
Weighted average remaining life, outstanding		4 years 9 months 18 days
Aggregate intrinsic value, outstanding, ending balance
Number of warrants, exercisable, ending balance	8,558,904	8,558,904				8,558,904
Weighted average exercise price, exercisable, ending balance	$ 10.79	$ 10.79				$ 10.79
Weighted average remaining life, exercisable		4 years 9 months 18 days
Aggregate intrinsic value, exercisable, ending balance
Warrant [Member] | Predecessor [Member]
Number of warrants, outstanding, beginning balance		8,560,562		2,154,352	2,154,352	2,154,352
Weighted average exercise price, outstanding, beginning balance		$ 1.52		$ 1.98	$ 1.98	$ 1.98
Number of warrants, Issued					6,406,210
Weighted average exercise price, issued					$ 1.37
Number of warrants, outstanding, ending balance					8,560,562		2,154,352
Weighted average exercise price, outstanding, ending balance					$ 1.52		$ 1.98
Weighted average remaining life, outstanding					1 year 9 months 18 days
Aggregate intrinsic value, outstanding, ending balance					$ 59,681
Number of warrants, exercisable, ending balance					8,560,562
Weighted average exercise price, exercisable, ending balance					$ 1.55
Weighted average remaining life, exercisable					3 years 10 months 24 days
Aggregate intrinsic value, exercisable, ending balance					$ 34,203
Number of warrants, Exercised
Weighted average exercise price, exercised

Schedule of Information Relat_2

Schedule of Information Related to Stock Warrants (Details) - $ / shares	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Dec. 31, 2022	Dec. 12, 2022
Warrant exercisable, weighted average remaining life in life		5 years 3 months 18 days	5 years 3 months 18 days
Exercise Price One [Member]
Warrant exercisable, weighted average remaining life in life			3 years 1 month 6 days
Exercise Price Two [Member]
Warrant exercisable, weighted average remaining life in life			9 years 6 months
Exercise Price Three [Member]
Warrant exercisable, weighted average remaining life in life		2 years 9 months 18 days	6 years 3 months 18 days
Exercise Price Four [Member]
Warrant exercisable, weighted average remaining life in life		9 years 3 months 18 days	8 years 3 months 18 days
Warrant [Member]
Weighted average exercise price, outstanding	$ 10.75		$ 10.75	$ 10.75
Number of warrants, outstanding	8,628,706		8,628,706	8,628,706
Warrants exercisable, weighted average remaining life in life	4 years 9 months 18 days
Number of warrants, exercisable	8,558,904		8,558,904
Warrant exercisable, weighted average remaining life in life			4 years 9 months 18 days
Warrant [Member] | Exercise Price One [Member]
Weighted average exercise price, outstanding	$ 5.03		$ 5.03
Number of warrants, outstanding	104,704		104,704
Warrants exercisable, weighted average remaining life in life			2 years
Number of warrants, exercisable	34,901		34,901
Warrant [Member] | Exercise Price Two [Member]
Weighted average exercise price, outstanding	$ 6.90		$ 6.90
Number of warrants, outstanding	1,271,904		1,271,904
Warrants exercisable, weighted average remaining life in life			4 years 10 months 24 days
Number of warrants, exercisable	1,271,904		1,271,904
Warrant [Member] | Exercise Price Three [Member]
Weighted average exercise price, outstanding	$ 11.50		$ 11.50
Number of warrants, outstanding	6,929,073		6,929,073
Warrants exercisable, weighted average remaining life in life			4 years 10 months 24 days
Number of warrants, exercisable	6,929,073		6,929,073
Warrant [Member] | Exercise Price Four [Member]
Weighted average exercise price, outstanding	$ 11.58		$ 11.58
Number of warrants, outstanding	323,026		323,026
Warrants exercisable, weighted average remaining life in life			1 year
Number of warrants, exercisable	323,026		323,026

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

10 Months Ended

11 Months Ended

12 Months Ended

Dec. 31, 2022

Jul. 08, 2022

Dec. 31, 2022

Mar. 31, 2021

Feb. 28, 2021

Mar. 31, 2023

Mar. 31, 2022

Jul. 31, 2020

Dec. 12, 2022

Dec. 31, 2022

Dec. 31, 2021

Feb. 20, 2023

Dec. 06, 2022

Sep. 16, 2022

Dec. 31, 2020

Short-Term Debt [Line Items]

Note principal amount

$ 3,961,000

Debt instrument interest rate

2%

conversion price

$ 1.58835

Issued to related party

[1]

$ 398,019

Financial Designation, Predecessor and Successor [Fixed List]

Successor

Successor

Successor

Predecessor

Predecessor

Successor

Predecessor

Amortization of debt discount

Accured interest

$ 709,608

Convertion of debt into shares

2,940,537

Derivative liabilities

$ 560,600

$ 788,700

Shares converted into common stock

583,831

Conversion description

The automatic conversion was pursuant to the share-settled redemption feature included in the original terms of the Notes which resulted in a conversion price of $1.58835 (80% of the $1.98542 fair value per share of the Predecessor common stock which was determined using the Business Combination exchange ratio of 5.037).

Predecessor [Member]

Short-Term Debt [Line Items]

Placement agent fees

$ 21,200

$ 2,000

$ 16,000

Financial Designation, Predecessor and Successor [Fixed List]

Predecessor

Predecessor

Predecessor

Amortization of debt discount

$ 32,184

$ 39,492

$ 317,833

Derivative liabilities

$ 1,167,601

560,600

Shares converted into common stock

2,940,537

Predecessor [Member] | Interest Expense [Member]

Short-Term Debt [Line Items]

Amortization of debt discount

$ 709,608

$ 317,833

Common Stock Payable [Member]

Short-Term Debt [Line Items]

Fair value price percentage

80%

Fair value per share

$ 1.98542

2021 Notes [Member]

Short-Term Debt [Line Items]

Note principal amount

5,230,000

Qualified equity financing exceeded proceeds

500,000

Accured interest

$ 428,888

2021 Notes [Member] | Series A Preferred Stock [Member]

Short-Term Debt [Line Items]

conversion price

$ 3.14

Convertion of debt into shares

1,802,193

Investors and Brokers [Member] | Unsecured Convertible Promissory Notes [Member]

Short-Term Debt [Line Items]

Note principal amount

$ 5,230,000

$ 5,230,000

$ 3,961,000

Debt instrument interest rate

6%

6%

Initial public offering

$ 20,000,000

conversion price

$ 3.25

$ 3.25

$ 3.25

Debt instrument fair value

$ 373,000

Fair value of put option

64,342

Debt instrument equity financing minimum

$ 500,000

$ 500,000

Embedded feature debt, description

The Company analyzed the embedded features of the 2021 Notes and determined that the 2021 Notes contained (i) an automatic conversion upon a Qualified Debt Financing which did not require bifurcation, (ii) an automatic conversion upon a Qualified Equity Financing at a fixed price of $3.25 per share which did not require bifurcation, (iii) an automatic conversion upon a Change of Control at a fixed price of $3.25 per share which did not require bifurcation, and (iv) a redemption feature upon default which did not require bifurcation.

The Company analyzed the embedded features of the 2021 Notes and determined that the 2021 Notes contained (i) an automatic conversion upon a Qualified Debt Financing which did not require bifurcation, (ii) an automatic conversion upon a Qualified Equity Financing at a fixed price of $3.25 per share which did not require bifurcation, (iii) an automatic conversion upon a Change of Control at a fixed price of $3.25 per share which did not require bifurcation, and (iv) a redemption feature upon default which did not require bifurcation.

Cash fee rate for placement agent fees

8%

8%

8%

Investors and Brokers [Member] | Unsecured Convertible Promissory Notes [Member] | Predecessor [Member]

Short-Term Debt [Line Items]

Placement agent fees

$ 228,236

$ 228,236

$ 228,236

Investors and Brokers [Member] | Unsecured Convertible Promissory Notes [Member] | IPO [Member]

Short-Term Debt [Line Items]

Initial public offering

$ 20,000,000

Price per share rate

80%

Investors and Brokers [Member] | Unsecured Convertible Promissory Notes [Member] | Related Party [Member]

Short-Term Debt [Line Items]

Due to related parties

$ 25,000

Investors and Brokers [Member] | Unsecured Convertible Promissory Notes [Member] | Related Party [Member] | 2021 Notes [Member]

Short-Term Debt [Line Items]

Issued to related party

$ 3,150,000

$ 3,150,000

[1]See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Predecessor [Member] - USD ($)	11 Months Ended	12 Months Ended
	Dec. 12, 2022	Dec. 31, 2022	Dec. 31, 2021
Reorganization, Chapter 11 [Line Items]
Broker fees		$ 0	$ 50,000
Proceeds from purchase of 2021 Notes	$ 0		$ 3,150,000